curriculum vitae taner demirer, m.d, facp professor of ... · professor of medicine and...
TRANSCRIPT
1
1
CURRICULUM VITAE
Taner Demirer, M.D, FACP Professor of Medicine and Hematology/Oncology
PERSONAL INFORMATION Date of Birth : 03/27/61 Place of Birth: Ankara, Turkey. Home Address: Üniversiteler Mahallesi, 1623. Sok No: 7 Bilkent-Ankara
TURKEY
Professional address: Ankara University Medical School, Dept. of
Hematology/Oncology and Bone Marrow Transplant Unit,
Cebeci Hospital, Ankara-Turkey.
Cell Phone: +90-532-325-1065 Business Phone: +90-312-595-7376 Fax: +90-312-466 -3717 E-Mail: [email protected]
SPECIALITIES: American Board Certified in Internal Medicine (1993) American Board Certified in Medical Oncology (1997) American Board Eligible in Hematology
2
2
PRESENT and PAST ACADEMIC RANK AND POSITION
Research Associate, Dept. of Hematol / Oncology, Chicago Medical School (USA) 1988-
1989
Fellow of American College of Physicians (FACP) (July 1996)
Clinical Investigator, The Fred Hutchinson Cancer Research Center, Seattle (USA), 1996-
1997
Professor of Medicine, Ankara University Medical School, Dept. of Hematology and Bone
Marrow Transplant Unit (CIC 617). (1997- )
Chairperson of the EBMT Solid Tumor Working Party (March 2001-2007).
Member for FECS (Federation of European Cancer Societies) (March 2001-2007).
President of the Turkish Cancer Advisory Board (June, 2003-2005).
Member of Blood and Blood Products Committee of Turkish Ministry of Health (1999-
2004).
Member of the Imported Blood Products Committee of Turkish Ministry of Health 1999-
2002).
Member of the Apheresis Committee of Turkish Ministry of Health (2000-2003)
Chief of Drug Registration and Licensing Committee of Turkish Ministry of Health (2001-
2004)
National Director of the EU 6th Framework Program (2002-2003)
3
3
Principal Member of The Turkish Academy of Sciences (2012- )
Member, Stem Cells Working Group of The Turkish Academy of Sciences (2012- )
Principal Member of The European Academy of Sciences and Art (EASA) (2013- )
Director, Cancer Working Group of The Turkish Academy of Sciences (2013- )
Member, Member Selection Committee of Global Network of Science Academies-IAP
(2013- )
Council Member of the Turkish Academy of Sciences (2015- )
EDUCATION
Medical School: Ankara University ,Medical School Ankara-Turkey. Degree: M.D. Date: 08/01/84
Research Associate, Chicago Medical School, North Chicago, Illinois (1988-1989)
Flow Cytometry and applications:
a) Prostate Cancer: (Chicago Medical School, Dept. of
Hematology and Oncology, Chicago, Illinois), USA (1989).
b) Mediterranean Lymphomas –IPSID: Medical College of
Wisconsin, Dept. of Hematology/Oncology, Milwaukee, Wisconsin,
4
4
USA (1990-1992).
Internship: Chicago Medical School (IL-USA) 1989-1990 Residency: Internal Medicine, Medical College of Wisconsin (WI-USA) 1990-1992 Fellowship:
Medical Oncology, The Fred Hutchinson Cancer Research Center, University of
Washington, School of Medicine, (Seattle USA) 1992 –1994.
Hematology and Bone Marrow Transplantation, The Fred Hutchinson Cancer
Research Center, University of Washington, School of Medicine, (Seattle USA)
1994-1996
Examinatiıons passed in the USA
Educational Commission for Foreign Medical Graduates (ECFMG)
23, 24 Temmuz 1986
Federal Licensing Examination (FLEX) 21, 22, 23 Haziran 1990
American College of Physicians Self - Assesment Examination (Aralık 1992)
American Board of Internal Medicine (ABIM) 15,16 Eylül 1993
American Board of Medical Oncology 21 Kasım 1997.
5
5
BOARD CERTIFICATIONS ECFMG Certificate: July 24, 1989 Federal License Examination (FLEX) (Part I-II) : June 20-22, 1990 Diplomate, American Board of Internal Medicine (ABIM): Sept. 21-22, 1993 Diplomate, American Board of Medical Oncology: November , 1997. Board eligible in Hematology
MEDICAL LICENSURE Washington State (USA) (Since 1992)
Wisconsin (USA) (Since 1989)
HONORS/AWARDS
Third Highest degree in class of 550. Univ. of Ankara, School of Medicine
(08/01/84)
Fellow of American College of Physicians (FACP), July 1996.
Outstanding Clinical Research Award, The Fred Hutchinson Cancer Research
Center, Seattle, WA, (April,1996)
ROCHE Hematology Award of Turkey October 1998
Junior Chamber of International (JCI) Award September 27, 2000
6
6
Science Award of The Scientific and Technical Research Council of Turkey, July
2002.
Science Award of The Bayındır Hospital Medical Center, 2004
Grand Honour Award of Turkish Parliament, 2014
CITATIONS
As of January, 2018, number of citations for publications cited in the Science
Citaton Index is 3965 and H value of 34 (ISI Web of Knowledge) and 37
(Scopus).
CONGRESS ACTIVITIES
Scientific Committee of the Second International High-Dose Chemotherapy Congress which was be held on April 9-12th 2002 in Banff, Canada.
President and Scientific Chairman of the EBMT annual meeting in March 2003 in Istanbul, Turkey. President of the (First, second, third and fourth) (2004-2007) National Medical Oncology Congress of Turkey President of the (First to sixth) Lymphoma-Myeloma Congress of Turkey (2009-2014)
Co-President of EBMT Annual Meeting in March 2015 in Istanbul, Turkey
7
7
INVITED SPEAKER OR CHAIRSHIPS IN INTERNATIONAL MEETINGS
1) ESH-EBMT Euroconference on Blood and Marrow Transplantation
(3-7 November 2001, Athens Greece)
Meet the Expert Session:
Speaker: Stem cell Transplantation in Patients with Solid Tumors (November 5,
2001).
2) 28th Annual Meeting of European Group for Blood and Marrow
Transplantation and 18th Meeting of Nurses Group (March 2002, Montreux,
Switzerland).
Speaker: Results of Breast Cancer Survey. Chairship: Solid Tumor Working
Party Session. (25-03-02, 15-17PM, Miles Davis Hall, Level-A3)
3) 28th Annual Meeting of European Group for Blood and Marrow
Transplantation and 18th Meeting of Nurses Group (March 2002, Montreux,
Switzerland). Chairship: Solid Tumor Working Party Oral Presentations. (26-03-
02, 13-15 PM, Leman A, Petit Palais)
4) Second International Conference on High Dose Chemotherapy-Innovation
and Evolution (April 9-12th 2002, Banff, Alberta, Canada)
Session I: High-Dose Chemotherapy (April 10, 2002)
Chairs: P. Stiff (USA), T. Demirer (Turkey)
Speaker: What’s going on in Europe (T. Demirer)
5) ‘IXth International Symposium on Biomedical Science & Technology ‘ (19-
22 Eylül 2002, Antalya, Turkey).
Speaker: CD34+ and Dendritic Cells in the field of Medical Oncology.
8
8
6) Second Euroconference and 5th workshop on clinical cytometry: From
pathogenesis to therapy (September 19-22, 2002 in Urbino).
Speaker: CD41+ and CD42+ hematopoietic progenitor cells as predictors of
platelet engraftment after stem cell transplantation.
7) Second International Congress on Advances in Hematology, Oncology
and BMT & First Nursing Meeting (September 25-29, 2002, Tehran, Iran).
Speaker: a) Autologus transplantation in solid tumors
Speaker: b) High-dose adjuvant chemotherapy in breast cancer.
8) Nuovi Standard Nella Prevenzione, Diagnosi E Cura in Oncologia
(Castelfranco Veneto, Italy 8-9 November, 2002).
Speaker: High-dose chemotherapy in solid tumors: European activity.
9) 3rd EBMT/AMGEN Workshop on Reduced Intensity Transplants (Zurich,
13-14 February, 2003.
Chairshipı: Reduced intensity transplants in olid tumors.
Introduction: Demographics in the Europe.
10) 29th Annual Meeting of European Group for Blood and Marrow
Transplantation and 19th Meeting of Nurses Group (March 23-26, 2003 in
Istanbul).
a) Chairship: (Schering-German Symposium on March 23rd) Reduced intensity
transplants.
b) Chairship (Novartis Symposium on March 23rd) CML, transplant and
Gleevec.
c) Chairship: Opening session (EBMT Lecture and Van Bekkum Award, March
23rd)
d) Chairship: Presidential symposium (March 24th).
9
9
e) Speaker: (Novartis Symposium on March 23, 2003): Imatinib or transplant-
Case studies
f) Speaker: Solid Tumors Working Party Session (March 24th)
g) Speaker: Role of stem cell transplantation in solid tumors-Ovarian cancer
(Educational Session, March 25th).
h) Chairship: GVT effects in the related and unrelated transplants in patients
with refractory solid tumors(March 26th).
11) ECCO-12, The European Cancer Conference (Copenhagen, 21-25
September 2003).
Speaker: Teaching Lecture: The status of bone marrow transplant clinical trials
(Monday, 22nd of September).
12) International workshop on high-dose chemotherapy in solid tumors
(Ravenna, Italy, 6-7 February 2004).
a) Chairship: High-dose chemotherapy in Breast cancer
b) Speaker: Summary of High-dose chemotherapy in solid Tumors.
13) Second Asian Pacific Bone marrow Transplantation Congress (Tehran,
Iran, Nov 18-20, 2004).
a) Speaker: Current status of High-dose chemotherapy and autologous stem
cell support in solid tumors (Nov 18, 2004).
b) Speaker: Nonmyeloablative stem cell transplantation in solid tumors (Nov 19,
2004)
10
10
14) 30th Annual Meeting of European Group for Blood and Marrow
Transplantation and 20th Meeting of Nurses Group (March 28-31, 2004 in
Barcelona).
a) Speaker and Chairship: Solid Tumors Working Party Session (March 29th,
2004)
b) Chairship: Transplantation in Solid Tumors (Workshop) (March 31st , 2004)
c)Speaker: Current Indications of Autologous Transplants (March 31st, 2004).
15) 31st Annual Meeting of European Group for Blood and Marrow
Transplantation and 21st Meeting of Nurses Group (March 20-23, 2005 in
Prague).
a) Speaker and Chairship: Solid Tumors Working Party Session (March 22th,
2005)
b) Speaker: (Educational Session) Stem cell mobilization: Factors influencing
stem cell collection (March 21st, 2005)
16) 15th Congress of the Interdisciplinary European Society for
Haemapheresis and Haematotherapy (ESFH). (October 6, 2005)
Speaker: Conference: Patients hard to mobilize in growth factors (45 minutes)
17) ECCO-13, The European Cancer Conference (Paris, October 30th-
November 3rd 2005).
a) Chairship: Non-myeloablative transplantation in solid tumors (November 2,
2005).
b) Speaker: Results in other solid tumors (November 2, 2005)
11
11
18) Second ATST Meeting-Allogeneic Transplantation in Solid Tumors,
Stresa, Italy, October 7-8, 2005.
Chairship: Graft-vs-Solid Tumor: Anectodal reports session
19) 32nd Annual meeting of the EBMT , March 19-22, 2006 in Hamburg,
Germany.
a) Chairship: Solid Tumor Working Party session (March 20, 2006)
b) Speaker: Introduction and Meta-analysis project for nreast cancer. (STWP
Session, March 20, 2006)
c) Speaker: (Educational session-6): Autologous transplantation in solid tumors
March 21, 2006)
20) The tenth ESH-EBMT training course on blood and marrow transplantation.
May 24-28, 2006, Hyatt Hotel, Warsaw, Poland.
a) Speaker: Autologous transplant in solid tumors. May 27, 2006.
21) 41st Annual meeting of the EBMT, March 2014 in Istanbul, Turkey.
a) Chairship: Solid tumors Working Part Session, March, 2014
b) Speaker: High-dose chemotherapy and ASCT in patients with ovarian cancer,
March 2014.
22) 18th International Pharmaceutical Technology Symposium. (18-09-16)
Session Chair: Clinical Trials and Future Perspectives
Speaker: A Review of Clinical Phase Studies and Current Problems in Turkey.
23) 2. Türkey-Azerbaijan Oncology Days (20-23 Ekim 2016, Bakü)
Topic: General Principles of Bone Marrow Transplantation (21-10-16).
12
12
MEMBER OF EDITORIAL REVIEW BOARD OF MAJOR JOURNALS 1) Bone Marrow Transplantatıon (1998-2014). 2) Stem Cells and Development (1999-2012) 3) World Journal of Hematology (2015- )
PROFESSIONAL MEMBERSHIPS AND SOCIETIES American College of Physicians (ACP) American Society of Clinical Oncology (ASCO) The American Society of Hematology (ASH) The American Society for Blood and Marrow Transplantation (ASBMT) Wisconsin Medical Society (Wisconsin-USA) Milwaukee County Medical Society (Wisconsin USA) Washington State Medical Society (Seattle-USA) European Bone Marrow Transplantation (EBMT) European Hematology Association (EHA) European Society of Medical Oncology (ESMO) Turkish Society of Hematology Turkish Society of Clinical Oncology
13
13
RESEARCH INTERESTS 1) High dose chemotherapy with recombinant human growth factors for
cytoreduction and peripheral blood stem cell mobilization.
2) High dose chemotherapy followed by autologous stem cell rescue for treatment of
ovarian, breast, testicular and small cell lung cancer.
3) Autologous stem cell transplantation using peripheral blood stem cells in patient
with multiple myeloma, lymphoma and acute myelogenous leukemias.
4) Allogeneic stem cell transplantation with reduced intensity regimens in patients
with refractory solid tumors.
5) Allogeneic peripheral blood stem cell transplantation in patients with hematologic
malignancies.
CONDUCTED STUDIES
I) Studies Chaired or Co-Chaired by Dr. DEMIRER at the Fred
Hutchinson Cancer Research Center, Previously (1992-1997).
Granulocyte-colony stimulating factor (G-CSF) alone for peripheral blood stem
cell (PBSC) mobilization in patients with hematologic malignancies.
Chemotherapy based regimens for cytoreduction and PBSC mobilization in
patients with lymphoma, breast and ovarian cancer.
14
14
Cyclophosphamide, paclitaxel and rhG-CSF for cytoreduction and PBSC
mobilization in patients with breast and ovarian cancer.
Busulfan and cyclophosphamide as a conditioning regimen in patients with
breast cancer.
Phase-II study of High-dose chemotherapy with busulfan, melphalan and
thiotepa followed by autologous stem cell rescue in patients with advanced stage
ovarian cancer.
Phase I-II trial of allogeneic marrow transplantation following cyclophosphamide
and escalating doses of hyper-fractionated total body irradiation in patients with
advanced lymphoid malignancies.
Phase-I dose escalation of busulfan based on targeted plasma levels: Busulfan,
cyclophosphamide and fractionated total body irradiation for allogeneic marrow
transplantation for advanced acute and chronic myelogenous leukemia.
Phase-I dose escalation of busulfan based on targeted plasma levels: Busulfan,
cyclophosphamide and fractionated total body irradiation for autologous or
syngeneic marrow transplantation for advanced acute and chronic myelogenous
leukemia.
High-dose therapy followed by autologous hematopoietic stem cell infusion for
patients with multiple myeloma.
Autologous marrow and/or PBSC transplantation in patients with acute
myelogenous leukemia: Engraftment characteristics and the incidence of relapse
with PBSCs.
15
15
Allogeneic peripheral blood stem cell mobilization and transplantation in patients
with advanced hematological malignancies.
II) Studies Chaired or Co-Chaired by Dr. DEMIRER as chairman of the
EBMT Solid Tumors Working Party, (2001-2007).
A randomised study IT94 in relapsing germ cell tumours including patients in
incomplete remission.
Chairman: Taner Demirer (Ankara-Turkey), Principal İnvestigator: JL Pico, Bone
Marrow Transplantation Unit,Hematology Division, Institut Gustave Roussy, Rue
Camille Desmoulins, 94805 Villejuif Cedex, FRANCE
Randomised study (Random-ICE) EBMT phase-III randomized trial for small cell
lung cancer (started June 1997, Completed in 2004)
Chairman: Taner Demirer (Ankara-Turkey), Principal İnvestigator: Serge
Leyvraz, Centre Pluridisciplinaire d'Oncologie, Rue de Bugnon 26 CHUV-10,
1011 Lausanne, SWITZERLAND.
A phase III randomised study on advanced ovarian carcinoma started in April
1998 (OVCAT Study) and completed in 2004.
Chairman: Taner Demirer (Ankara-Turkey), Principal İnvestigator: J Ledermann,
Department of Oncology, University College London Medical School, 91 Riding
House Street, London W1P 8BT, UNITED KINGDOM.
PEGASE 03 High-dose cyclosphosphamide and Thiotepa after FEC for metastatic disease versus FEC alone
16
16
Chairman: Taner Demirer (Ankara-Turkey), Principal İnvestigator: P Biron,
Centre Leon Berard,Rue Laennec 28 ,69373 Lyon Cedex 08, FRANCE
PEGASE 05 A new phase 2 study on non metastatic inflammatory breast cancer
Chairman: Taner Demirer (Ankara-Turkey), Principal İnvestigator: P Viens,
Institute Paoli l. Calmettes, 232 Boulevard de Ste. Marguerite, 13273 Marseille
Cedex 9, FRANCE.
Phase I study on the role of allografting in solid tumours
Chairman: Taner Demirer (Ankara-Turkey), Principal İnvestigator: D
Niederwieser, Klinik für Innere Medizin, Abt. Hematologie/Onkologie, Universitat
Leipzig, Johannisallee 32, D-7010 Leipzig, Germany.
A randomised phase 3 study on relapsed platinum sensitive epithelial ovarian
cancer (Closed).
Chairman and Principal İnvestigator: T Demirer, Ankara University Medical
School, Ibn-i Sina Hospital, EBMT Office, Floor 05, Sihhiye, 06100 Ankara,
Turkey.
A randomised phase 3 study on completely responding metastatic breast cancer.
A joint protocol of the EBMT and MDACC. Chairman: T. Demirer (Ankara-
Turkey), Principal investigators: G. Hortobagyi, MDACC, Texas, USA ; N. Ueno,
MDACC, Texas, USA; and T. Demirer (Ankara-Turkey).
A randomised phase 3 study on partially responding metastatic breast cancer. A
joint protocol of the EBMT and GITMO.
Chairman: T. Demirer (Ankara-Turkey), Principal investigators: M. Aglietta and F.
Montemurro, Turin, Italy.
17
17
Phase-II randomized study of intra-familial allogeneic stem cell transplantation
for patients suffering from metastatic renal cell carcinoma. A joint protocol of the
EBMT and French National Group. Chairman: T. Demirer (Ankara-Turkey),
Principal investigator: D. Blaise (Marseille, France).
III) RETROSPECTIVE studies coordinated by Dr. Demirer in related
to autologous stem cell transplantation as chairman of the EBMT
STWP:
i) EBMT retrospective study on female germ cell tumors
Study chair: Dr. Luca Castagna
E-mail:[email protected]
ii) EBMT retrospective study on soft tissue sarcoma
Study chair: Dr. Peter Reichardt
E-mail:peter.reichardt@charıte.de
iii) EBMT retrospective study on Osteosarcoma
Study chair: Dr. Jeremy Whelan
E-mail: [email protected]
iv) EBMT retrospective study on Ovarian Carcinoma patients CR1 at graft
Study chair: Dr. Carmelo Bengala
E-mail: [email protected]
v) Retrospective study on Neuroblastoma
Study chair: Dr. Frederique Rousseau
E-mail: [email protected]
vi) Retrospective study on Ewing`s Sarcoma and PNET
Study chair: Dr. Amelia Tienghi and Alexia Bertuzzi
E-mail: [email protected]
vii) Retrospective study on Astrocytoma
Study chair: Dr. Olivier Bay
18
18
E-mail: [email protected]
viii) Retrospective study on Medulloblastoma
Study chair: Dr. Paolo Pedrazzoli
E-mail: [email protected]
ix) Retrospective study on Melanoma
Study chair: Dr. Bernd Hertenstein (not confirmed)
E-mail: [email protected]
x) Retrospective study on Thymoma(not confirmed)
Study chair: Dr. Didier Blaise
E-mail: [email protected]
xi) Retrospective study on Gastric Carcinoma
Study chair: Dr. Reinhard Adreesen
E-mail: [email protected]
xii) Retrospective study on Small Cell Lung Cancer
Study chair: Dr. Giovanni Rosti, Dr. Ugo De Giorgi
E-mail: [email protected] , [email protected]
XIII) Retrospective study on Non Small Cell Lung Cancer(not confirmed)
Study chair: Dr. Giovanni Rosti, Dr. Ugo De Giorgi
E-mail: [email protected] , [email protected]
xiii) Retrospective study on Unknown Origin Adenocarcinoma
Study chair: Dr. Fikret Arpaci
E-mail: [email protected]
xiv) Retrospective study on Wilms` tumors
Study chair: Dr. Emel Unal
E-mail: [email protected]
xv) Retrospective study on Inflammatory Breast cancer
Study chair: Dr. Ugo De Giorgi
E-mail: [email protected]
19
19
IV) Meta-analysis project in breast cancer- An international task
force on behalf of the EBMT Solid Tumor Working Party
Demirer T (Chairman) Project Coordinator (Turkey)
Berry A.D, PhD, USA, (American Principal Investigator)
This project was a joint venture of EBMT and MDACC under
coordinatorship of Professor Demirer, chairman of the EBMT STWP
(2001-2007). It started in 2007 and completed in 2010. All prospective
radomized trails investigating the efficacy of high-dose chemotherapy
(HDC) and autologous stem cell transplant(ASCT) in patients with
breast cancer in the adjuvant and metastatic settings were included in
this meta-analysis. Data of 15 trials in the adjuvant and 6 trials in the
metastatic setting done worldwide have been accumulated at the dept,
of Statistics of MDACC in Houston, Texas. Results of this meta-
analysis were published in the Journal of Clinical Oncology as 2
consecutive manuscripts in 2011. Results of this meta-analysis has
shed a valuable light on this issue. Based on this analysis HDC and
ASCT showed statistically significant progression free survival
advantage in both adjuvant and metastatic settings compared to
conventional chemotherapy. But there was no overall survival
advantage in both groups. Furthermore, advantage of HDC and ASCT
in some subgroup of breast cancer patients were defined and a new
randomized trial was kicked off in Netherland, in 2012, targeting the
patients with triple negative and BRCA-1 like disease.
20
20
V) RETROSPECTIVE studies coordinated by Dr. Demirer in related to
allogeneic stem cell transplantation in solid tumors as chairman of
the EBMT STWP:
i) Retrospective analysis of EBMT allograft in renal cancer
Study chair: Lisbeth Barkholt
E-mail: [email protected]
ii) Prognostic factors in EBMT renal cancer experience
Study chair: Jacopo Peccatori
E-mail: [email protected]
iii) Retrospective analysis of EBMT/IBMTR experience of allograft in breast cancer
Study chair: Dietger Niederwieser
E-mail:[email protected]
iv) Retrospective analysis of EBMT allograft in ovarian cancer
Study chair: Olivier Bay
E-mail: [email protected]
v) Retrospective analysis of EBMT colorectal cancers
Study chair: Massimo Aglietta
E-mail: [email protected]
vi) Nonmyeloablative transplants in soft tissue sarcomas
Study chair: Paolo Corradini
E-mail: [email protected]
vii) Histopathology of renal cell cancer and patient survival after allogeneic SCT
Study chair: Lisbeth Barkholt, E-mail: [email protected]
21
21
VI) Studies chaired or co-chaired by Dr. DEMIRER in Turkey.
Phase-I dose escalation study of high-dose thiotepa, melphalan and carboplatin
(TMCb) followed by autologous peripheral blood stem cell transplantation in
patients with solid tumors and hematologic malignancies.
Epirubicin, carboplatin and paclitaxel versus Carboplatin and paclitaxel in
patients with de novo epithelial ovarian cancer: Phase IV randomized study.
Phase-II study of high-dose thiotepa, melphalan and carboplatin (TMCb)
followed by autologous peripheral blood stem cell transplantation in patients with
solid tumors and hematological malignancies.
Randomized phase-III trial of interferon administration following high-dose
chemotherapy and autologous peripheral blood stem cell transplantation in
patients with multiple myeloma (Multi-center study started in 2002).
Randomized study of rhG-CSF administration starting on day 0 and day 5 versus
none in patients with solid tumors following high-dose chemotherapy and
autologous stem cell transplantation.
22
22
PUBLICATIONS
Taner Demirer, MD, FACP
1. Demirer T, Icli F, Uzunalimoglu O, Kucuk O: Diet and Stomach Cancer
Incidence. A case control study in Turkey. "CANCER", Vol:65, No:10, pp:2344-
2348,1990.
2. Kucuk O, Demirer T, Gilman-sachs, Taw I, Mangold M, Singh S and Westerman
M P: Intratumor heterogeneity of DNA ploidy and correlations with clinical stage and
histologic grade in prostate cancer. "JOURNAL of SURGICAL ONCOLOGY" Vol:54,
pp:171-174, 1993.
3. Demirer T, Dail D, and Aboulafia D : Four varied cases of intravascular
lymphomatosis. "CANCER", March 15, Volume 73, No.6, pp: 1738-1745, 1994.
4. Bensinger W, Demirer T, and Buckner C.D: Factors influencing stem cell
mobilization and engraftment kinetics after transplantation of peripheral blood stem
cells (PBSC's). Recent advances in hematopoietic stem cell transplantation-
clinical progress, new technologies and gene therapy. University of California, San
Diego School of Medicine. Meeting Report, pp: 109-116, March 10-12, 1994.
5. Demirer T, Buckner C.D, Lilleby K, Weaver CH, Longin K, Appelbaum F,
Bensinger W: Failure of a single cycle of high dose cyclophosphamide followed by
intensive myeloablative therapy and autologous stem cell transplantation to improve
outcome in relapsed disease. "CANCER" Vol:74, no.2, pp:715-721,1994.
23
23
6. Demirer T, Ravits J, Aboulafia D: Lambert-Eaton Myasthenic Syndrome
associated with pulmonary large cell neuroendocrine carcinoma. "SOUTHERN
MEDICAL JOURNAL", Vol:87, No:11, pp:1186-1189,1994.
7. Demirer T, Uzunalimoglu O, Koethe S, Kucuk O, McFadden W.P, Uzunalimoglu
B, Anderson T: Flow cytometric measurement of proliferation-associated nuclear
antigen P105 and DNA content in immuno-proliferative small intestinal disease.
"JOURNAL OF SURGICAL ONCOLOGY", Vol:58, No:1, pp:25-30, (January), 1995.
8. Aboulafia D, Demirer T: Diffuse Myelonecrosis following Fludarabin
administration in a patient with indolent lymphoma. "LEUKEMIA & LYMPHOMA", vol:
19, pp:181-184, 1995.
9. Demirer T, Weaver CH, Buckner CD, Petersen FB, Bensinger WI, Sanders J,
Clift RA, Anasetti C, Martin P, Storb R, Appelbaum FR: High-dose cyclophosphamide,
carmustine, and etoposide (CBV) followed by allogeneic bone marrow transplantation in
patients with lymphoid malignancies who had received dose-limiting radiation therapy.
"JOURNAL of CLINICAL ONCOLOGY", Vol:13, No:3 (March), page:596-602, 1995.
10. Bensinger W.I, Weaver C.H, Appelbaum F.R, Rowley S, Demirer T, Sanders
J.E, Storb R, Buckner C.D. Transplantation of allogeneic peripheral blood stem cells
mobilized by recombinant human granulocyte colony stimulating factor (rhG-CSF).
"BLOOD", Vol:85, No:6, pages:1655-1658, 1995.
11. Demirer T, Buckner C.D, Petersen F.B, Appelbaum F, Rowley S, Sanders J,
Storb R, Benyunes MC, Fefer A, and Bensinger W. et al: Rapid engraftment after
autologous transplantation utilizing marrow and recombinant granulocyte-colony
stimulating factor (G-CSF) mobilized peripheral blood stem cells in patients with acute
myelogenous leukemia. "BONE MARROW TRANSPLANTATION", Vol:15, No:6,
24
24
pp:915-922, June 1995.
12. Demirer T, Bensinger WI. Optimization of peripheral blood stem cell collections.
"CURRENT OPINION in HEMATOLOGY", Vol:2, No:3, pages:219-226, 1995.
13. Demirer T, Gooley T, Buckner CD, Petersen FB, Lilleby K, Rowley S, Sanders J,
Storb R, Appelbaum FR, Bensinger WI: The influence of total nucleated cell dose from
marrow harvests on outcome in patients with acute myelogenous leukemia undergoing
autologous transplantation. "BONE MARROW TRANSPLANTATION", Vol:15, No:6,
pp:907-913, June 1995.
14. Demirer T, Petersen F.B, Appelbaum F.R, Sanders J.E, Deeg J, Storb R, Doney
K, Bensinger W.I, Shannon-Dorcy K. and Buckner C.D. Allogeneic marrow
transplantation following cyclophosphamide and escalating doses of hyper-fractionated
total body irradiation in patients with advanced lymphoid malignancies-A phase I-II trial.
"INTERNATIONAL J of RADIAT ONCOL BIOL. PHYS" Vol:32, No:4, pp:1103-1109,
1995.
15. Demirer T, Rowley S, Buckner C.D, Appelbaum F.R., Lilleby K, Storb R,
Bensinger W.I. Peripheral blood stem cell (PBSC) collections after paclitaxel,
cyclophosphamide and recombinant human granulocyte-colony stimulating factor in
patients with breast and ovarian cancer. "JOURNAL OF CLINICAL ONCOLOGY",
Vol:13, No:7, pp:1714-1719, July 1995.
16. Bensinger WI, Appelbaum F, Rowley S, Storb R, Sanders J, Gooley T, Demirer
T, Schiffman K, Weaver C, Clift R, Chauncey T, Klarnet J, Montgomery P, Petersdorf S,
Weiden P, Witherspoon R, and Buckner CD: Factors that influence collection and
engraftment of autologous peripheral blood stem cells. "JOURNAL OF CLINICAL
ONCOLOGY" Vol:13, No:10, pp:2547-2555, October 1995.
25
25
17. Bensinger WI, Demirer T, Rowley S, Buckner CD: Factors predictive of rapid
engraftment after peripheral blood stem cell infusions. "BONE MARROW
TRANSPLANTATION" Vol:15, Suppl:3, pages: 83-85, 1995.
18. Bensinger WI, Clift RA, Anasetti C, Appelbaum FR, Demirer T, Rowley S,
Sandmaier BM, Torok-Storb B, Storb R, and Buckner CD: Transplantation of
allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte-
colony stimulating factor. "STEM CELLS" Vol:14, No:1, pages:90-105, 1996.
19. Demirer T, Buckner CD, Bensinger WI: Optimization of peripheral blood stem
cell mobilization. "STEM CELLS" Vol:14, No:1, pages:106-116, 1996.
20. Bensinger WI, Buckner CD, Rowley S, Demirer T, Storb R, and Appelbaum FR.
Transplantation of allogeneic CD34+ peripheral blood stem cells (PBSC) in patients
with advanced hematologic malignancy. ‘BONE MARROW TRANSPLANTATION’
Vol:17 (Suppl.2): S 38-39, 1996.
21. Bensinger WI, Buckner CD, Demirer T, Storb R, Appelbaum FR.
Transplantation of allogeneic peripheral blood stem cells, Proceedings of the First
ınternational Symposium on Allogeneic Peripheral Blood Progenitor Cell
Transplantation, An EBMT Symposium. ‘BONE MARROW TRANSPLANTATION’
Vol:17 (Suppl.2): S56-S57, 1996.
22. Demirer T, Buckner CD, Appelbaum FR, Lambert K, Bensinger WI, Clift R, Storb
R, Slattery JT: Busulfan, cyclophosphamide and fractionated total body irradiation for
allogeneic marrow transplantation for advanced acute and chronic myelogenous
leukemia: Phase I dose escalation of busulfan based on targeted plasma levels. ‘BONE
MARROW TRANSPLANTATION" Vol:17, pages:341-346, 1996.
26
26
23. Demirer T, Buckner CD, Appelbaum FR, Clift R, Storb R, Myerson D, Lilleby K,
Rowley S, Bensinger WI: High-dose busulfan and cyclophosphamide followed by
autologous transplantation in patients with advanced breast cancer. "BONE
MARROW TRANSPLANTATION", Vol:17, pp:769-774, 1996.
24. Demirer T, Buckner CD, Appelbaum FR, Bensinger WI, Sanders J, Lambert K,
Clift R, Fefer A, Storb R, Slattery JT: Busulfan, cyclophosphamide and fractionated total
body irradiation for autologous or syngeneic marrow transplantation for acute and
chronic myelogenous leukemia: Phase I dose escalation of busulfan based on targeted
plasma levels. "BONE MARROW TRANSPLANTATION", Vol: 17, pp:491-495, 1996.
25. Schiffman K, Bensinger WI, Appelbaum FR, Rowley S, Lilleby K, Clift R, Weaver
CH, Demirer T, Sanders J, Petersdorf S, Gooley T, Weiden P, Zuckerman N,
Montgomery P, Maziarz R, Klarnet JP, Trueblood K, Storb R, Buckner CD: Phase II
study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood
stem cell support in patients with malignant disease. "BONE MARROW
TRANSPLANTATION", Vol: 17, pp:943-950, 1996.
26. Bensinger WI, Appelbaum FR, Demirer T, Torok-Storb B, Storb B, Buckner CD:
Transplantation of allogeneic peripheral blood stem cells. "STEM CELLS" Vol:13
(Suppl 3), pp 63-70, 1995.
27. Brunvand MW, Appelbaum FR, Soll E, Lilleby K, Clift R, Gooley T, Bensinger WI,
Weaver CH, Rowley SD, Fefer A, Press OW, Storb R, Sanders J, Martin PL, Chauncey
T, Maziarz RT, Weiden P, Demirer T, Holmberg LA, Schiffman K, McSweeney PA,
Maloney DG, Buckner CD: High-dose fractionated total-body irradiation, etoposide and
cyclophosphamide for treatment of malignant lymphoma: Comparison of autologous
bone marrow and peripheral blood stem cells. "BONE MARROW
TRANSPLANTATION", Vol:18, pp: 131-141, 1996.
27
27
28. Bensinger WI, Rowley SD, Demirer T, Appelbaum FR, Lilleby K, Schiffman K,
Clift RA, Barnett T, Storb R, Chauncey T, Maziarz RT, Klarnet J, Gooley TA, Fefer A,
McSweeney PA, Holmberg L, Maloney DG, Weaver CH, Buckner CD: High-dose
therapy followed by autologous hematopoietic stem cell infusion for patients with
multiple myeloma. "JOURNAL OF CLINICAL ONCOLOGY", Vol:14, No:5, pp:1447-
1456, 1996.
29. Demirer T, Buckner CD, Gooley T, Appelbaum FR, Rowley S, Chauncey T,
Lilleby K, Storb R, Bensinger WI: Factors influencing collection of peripheral blood
stem cells in patients with multiple myeloma. "BONE MARROW
TRANSPLANTATION", Vol:17, pp:937-941, 1996.
30. Demirer T, Petersen FB, Bensinger WI, Appelbaum FR, Fefer A, Rowley S,
Sanders J, Chauncey T, Storb R, Lilleby K, Buckner CD: Autologous transplantation
with peripheral blood stem cells collected after granulocyte-colony stimulating factor in
patients with acute myelogenous leukemia. "BONE MARROW TRANSPLANTATION",
Vol: 18, pp:29-34, 1996.
31. Bensinger WI, Demirer T, Buckner CD, Appelbaum FR, Storb R, Lilleby K,
Weiden P, Bluming AZ, Fefer A: Syngeneic marrow transplantation in patients with
multiple myeloma. "BONE MARROW TRANSPLANTATION", Vol:18, pp. 527-531,
1996.
32. Demirer T: Taxol with cyclophosphamide improves stem cell collection for
autologous use. "NATIONAL CANCER BULLETIN", pp:1-3, January-February, 1996.
28
28
33. Bensinger WI, Clift R, Martin P, Demirer T, Sanders J, Buckner CD: Allogeneic
peripheral blood stem cell transplantation in patients with advanced hematologic
malignancies: A retrospective comparison with marrow transplantation. ‘BLOOD’, Vol:
88, No:7, pp: 2794-2800, 1996.
34. Bensinger WI, Buckner CD, Shannon-Dorcy K, Rowley S, Appelbaum FR,
Benyunes M, CliftR, Mason P, Demirer T, Storb R, Lee M, Schiller G: Transplantation
of allogeneic CD34+ peripheral blood stem cells (PBSC) in patients with advanced
hematologic malignancy. BLOOD, Vol:88, No:11, pp:4132-4138, 1996.
35. Demirer T, Buckner CD, Storer B, Appelbaum FR, Storb R, Bensinger WI: The
effect of different chemotherapy regimens on peripheral blood stem cell mobilization
yield. ’JOURNAL OF CLINICAL ONCOLOGY’, Vol 15, No:2, pp:684-690,1997.
36. Bensinger W.I, Weaver C.H, Appelbaum F.R, Rowley S, Demirer T, Sanders
J.E, Storb R, Buckner C.D. Hot Papers-Transplantation of allogeneic peripheral blood
stem cells mobilized by recombinant human granulocyte colony stimulating factor . ’
THE SCIENTIST ’ vol:11, No:2, pp 15-16, 1997
37. Williams O, Demirer T, Lilleby K, Buckner CD, Bensinger WI. Tempo of
hematologic recovery correlates with peripheral blood CD34+ cell level in patients
undergoing stem cell mobilization. J. CLIN APHERESIS Vol:13, pp1-6, 1998.
38. Dilek I, Demirer T, Üstün C, Arat M, Koç H, Beksaç M, Erdi H, Anadolu R, Özcan
M, İlhan O, Akan H: Acquired icthyosis associated with chronic graft-versus-host
disease following an allogeneic peripheral blood stem cell transplantation in a patient
with chronic myelogenous leukemia. ‘BONE MARROW TRANSPLANTATION’ Vol:21,
pp: 1159-1161, 1998
29
29
39. Dilek İ, Uysal A, Demirer T, Koç H, Özcan M, Keleş H, Numanoğlu N, Üstün C,
Çiftçi E: Acute myeloblastic leukemia associated with hyperleukocytosis and diabetes
insipidus. ‘LEUKEMİA and LYMPHOMA’ Vol:30, pp: 657-660, 1998.
40. Holmberg LA, Demirer T, Rowley S, Buckner CD, Goodman G, Maziarz R,
Klarnet J, Zuckerman N, Harrer G, McCloskey R, Goldberg R, Nichols W, Jacobs A,
Weiden P, Montgomery P, Rivkin S, Appelbaum FR, Bensinger WI: High-dose
busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell
(PBSC) rescue in patients with advanced stage III-IV ovarian cancer. ‘BONE
MARROW TRANSPLANTATION’, Vol: 22, pp 651-659, 1998.
41. Üstün C, Arslan Ö, Beksaç M, Koç H, Gürman G, Özçelik T, Yılmaz B, İlhan O,
Akan H, Özcan M, Demirer T, Uysal A, Konuk N, Arat M, Dilek İ, Çelebi H, Şenol C: A
retrospective comparison of allogeneic peripheral blood stem cell and bone marrow
transplantation results from a single center, a focus on the incidence of GVHD and
relapse. ‘BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION’, Vol:5, pp 28-
35, 1999.
42. Demirer T, Bensinger WI, Buckner CD: Peripheral Blood stem cell mobilization
for high dose chemotherapy. ‘JOURNAL OF HEMATOTHERAPY’, Vol:8, pp 103-113,
1999.
43. Demirer T, Çelebi H, Arat M, Üstün C, Demirer S, Dilek İ, Özcan M, Ilhan O,
Akan H, Gürman G, Koç H: Autoimmune thrombocytopenia in a patient with small cell
lung cancer developing after chemotherapy and resolving following autologous
peripheral blood stem cell transplantation. ‘BONE MARROW TRANSPLANTATION’,
Vol:24, pp 335-337, 1999.
30
30
44. Üstün C, Çelebi H, Arat M, Özcan M, Dilek İ, Gürman G, Demirer T, İlhan O,
Keskin R, and Koç H. Treatment of aregeneratoric anemia following an ABO-
incompatible allogeneic peripheral blood stem cell transplantation: A case report.
‘THERAPEUTIC APHERESIS’ Vol:3, No:3, pp 275-277, 1999.
45. Rosti G, Ferrante P, Crown J, Pıco JL, Leyvraz S, Ledermann J, Demirer T,
Carıello A, Gıovanis P. High-dose chemotherapy and autologous stem cell
transplantation in patients with breast cancer and other solid tumors. A review of the
EBMT data.’TURKISH JOURNAL OF HEMATOLOGY’, Vol:16, No:3, pp. 19-26,
(Suppl), 1999.
46. Demirer T, Arat M, Koç H, Üstün C, Özcan M, Gürman G, Arslan Ö, Çelebi H,
İlhan O. Stem cell mobilization with cyclophosphamide, paclitaxel (or etoposide) and
recombinant granulocytecolony stimülating factor (rhG-CSF): Ibn-I Sina experience.
’TURKISH JOURNAL OF HEMATOLOGY’, Vol:16, No:3, pp. 83-84, (Suppl), 1999.
47. Demirer T, Çelebi H, Akçağlayan E, Üstün C, Demirer S, Ekinci C, Bahar K, Koç
H. An interesting clinical picture of immünoproliferatif small intestinal disease (IPSID):
Dıagnosis in oncology. ‘JOURNAL OF CLINICAL ONCOLOGY’ Vol:17, No:11, pp
3682-3684, 1999.
48. Üstün C, Özcan M, Gürman G, Çakır M, Erekul S, Akyol G, Arat M, Çelebi H,
İdilman R, Akan H, İlhan O, Demirer T, Beksaç M, Koç H: Differences in liver
pathology and clinical outcomebetween two patients with hepatitis B virus and graft
versus host disease. Pathology & Oncology Research, Vol:5, No:3, pp 229-232,
1999.
31
31
49. Demirer T, Ilhan O, Mandel NM, Arat M, Günel N, Çelebi H, Üstün C, Akan H,
Uysal A, Koç H: A phase-I dose escalation study of high-dose thiotepa, melphalan and
carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation
(PBSCT) in patients with solid tumors and hematologic malignancies. ‘BONE
MARROW TRANSPLANTATION’ Vol: 25, pp 697-703, 2000.
50. Arslan Ö, Coşkun Ş, Arat M, Çelebi H, Özcan M, Gürman G, Demirer T, Akan H,
İlhan O, Konuk N, Beksaç M, Uysal A, Koç H: Four years experience of Ibn-i Sina
Hospital in allogeneic peripheral blood stem cell transplantation for standard risk
leukemias. ‘ BONE MARROW TRANSPLANTATION’ Vol: 25, pp 1229-1232, 2000.
51. Demirer S, Aydıntuğ S, Üstün C, Tüzün A, Başaran Ö, Türkmen E, Coşkun Ş,
Çelebi H, Demirer T: Comparison of the efficacy of medium chain triglycerides with
long chain triglycerides in TPN patients with hematologic malignancies undergoing
hematopoietic peripheral blood stem cell transplantation. CLINICAL NUTRITION, Vol:
19, No: 4, pp 253-258, 2000.
52. Demirer T, O. Ilhan, M. Arat, K. Dalva, M. Beksaç, H. Çelebi, C. Üstün, H. Akan,
M. Özcan, G. Gürman, N. Konuk, A. Uysal, H. Koç: CD41+ and CD42+ hematopoietic
progenitor cells predict platelet engraftment after allogeneic peripheral blood stem cell
transplantation. JOURNAL OF CLINICAL APHERESIS, Vol: 16, pp 67-73, 2001.
53. Özcan M, Üstün C, Akçağlayan E, Akan H, Arslan Ö, İlhan O, Beksaç M,
Gürman G, Demirer T, Arat M, Çelebi H, Konuk N, Uysal A, Koç H. Recombinant
human granulocyte colony-stimulating factor(rhG-CSF) may accelerate hematopoietic
recovery after HLA identical sibling allogeneic peripheral blood stem cell
transplantation. BONE MARROW TRANSPLANTATION, Vol:27, pp 499-505, 2001.
32
32
54. Arat M, Ulusoy FV, Demirer T et al. Three cases of pericardial involvement of
multiple myeloma. LEUKEMIA & LYMPHOMA, Vol: 43, Pp 145-148, 2002.
55. Demirer T, Aylı M, Ozcan M, Gunel N, Haznedar R, Dağlı M, Fen T, Genc Y,
Dincer S, Arslan O, Gürman G, Demirer S, Özet G, Uysal A, Konuk N, İlhan O, Koc
H, Akan H: Mobilization of peripheral blood stem cells with chemotherapy and
recombinant human granulocyte-colony stimulating factor (Rh-GSCF): A randomized
evaluation of different doses of Rh-GSCF. BRITISH JOURNAL OF HAEMATOLOGY,
Vol: 116, pp 468-472, 2002.
56. Demirer T, Daglı M, Ilhan O, Aylı M, Haznedar R, Fen T, Günel N, Genc Y, Arat
M, Ozcan M, Arslan Ö, Seyrek E, Dincer S, Üstün T, Ustael N, Koc H, Müftüoğlu O,
Akan H. A randomized trial of assessment of efficacy of leukapheresis volumes, 8 liters
vs 12 liters. BONE MARROW TRANSPLANTATION, Vol: 29, pp 893-897, 2002.
57. Arslan O, Coşkun HŞ, Arat M, Soydan E, Özcan M, Gürman G, Çelebi H,
Demirer T, Akan H, Ilhan O, Konuk N, Uysal A, Beksac M, Koc H. The role of ABO
incompatibility in allogeneic peripheral blood stem cell transplantation. TURK J
HAEMATOL, Vol: 19(3):401-409, 2002.
58. Demirer T, İlhan O, Aylı M, Arat M, Daglı M, Özcan M , Haznedar R, Genç Y,
Fen T, Ayyılldız E, Dincer S, Arslan Ö, Gürman G, Konuk N, Dalva K, Uysal A, Koç H,
Özet G, Akan H. Monitoring of peripheral blood CD34+ cell counts on the first day of
apheresis is highly predictive for efficient CD34+ cell yield. THERAPEUTIC
APHERESIS, Vol: 6 (5), pp 384-389, 2002.
33
33
59. Demirer T, Aylı M, Daglı M, Haznedar R, Genc Y, Fen T, Dincer S, Ünal E,
Günel N, Seyrek E, Üstün T, Ustael N, Yıldız M, Sertkaya D, Ozet G, Müftüoğlu O.
Influence of post-transplant recombinant human granulocyte-colony stimulating factor
administration on peritransplant morbidity in patients undergoing autologous stem cell
transplantation. BRITISH JOURNAL OF HAEMATOLOGY, Vol:118, pp 1104-1111,
2002.
60. Demirer T, Aylı M, Daglı M, Fen T, Haznedar R, Ustael N, Ustun T, Oymak A,
Ozdel O, Müftüoğlu O. The effect of post-transplant spironolactone on daily potassium
requirements in patients undergoing autologous stem cell transplantation. BONE
MARROW TRANSPLANTATION, Vol: 30, pp 703-706, 2002.
61. Daglı M, Demirer T, Aylı M, Haznedar R, Günel N, Sucak G, Fen T, Moran M,
Üstün T, Aybirdi C, Çavuşoglu M, Dincer S, Uysal A. Plasmacytoma in the bilateral
breast. TURK J HAEMATOL, Vol: 19 (4): 477-480, 2002.
62. Kröger N, Zander AR, Martinelli G, Ferrante P, Moraleda JM, Da Prada GA,
Demirer T, Socie G, Rosti G on behalf of the Solid Tumors Working Party of the
European Group for Blood and Marrow Transplantation. Low incidence of secondary
myelodysplasia and acute myeloid leukemia after high dose chemotherapy as adjuvant
therapy for breast cancer patients: a study by the Solid Tumors Working Party of the
European Group for Blood and Marrow Transplantation. ANNALS OF ONCOLOGY
14:554-558,2003.
63. Demirer T, Uysal VA, Aylı M, Genc Y, Ilhan O, Koc H, Daglı M, Arat M, Gunel N,
Fen T, Dincer S, Ustael N, Yıldız M, Ustun T, Seyrek E, Ozet G, Muftuglu O, Akan H.
High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem
cell transplantation in patients with advanced breast cancer: a retrospective evaluation.
BONE MARROW TRANSPLANTATION, Vol:31, 755-761, 2003.
34
34
64. Demirer T .(Book Chapter). CD 34+ Cells in Hematopoietic Stem Cell
Transplantation. Chapter 8, pp 107-118. In TISSUE ENGINEERING, STEM CELLS,
AND GENE THERAPIES. (Advances in Experimental Mmedicine and Biology,
Volume 534). Edited by: M Elçin, Kluwer Academic/Plenum Publishers, New York,
2003.
65. Pedrazzoli P, Ferrante P, Kulekci A, Schiavo R, Giorgi U De, Carminati O,
Marangolo M, Demirer T, Siena S, and Rosti G, on behalf of the European Group For
Blood and marrow Transplantation (EBMT), Solid Tumors Working party. Autologous
hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation
of data from the European Group for Blood and marrow Transplantation (EBMT)
Registry 1990-1999. BONE MARROW TRANSPLANTATION, Vol:32, 489-494, 2003.
66. Kröger N, Damon L, Zander A R, Wandt H, Derigs G, Ferrante P, Demirer T,
Rosti G on behalf of the EBMT Solid Tumors Working Party. Secondary acute
leukemia following mitoxantrone based high-dose chemotherapy for primary breast
cancer patients. BONE MARROW TRANSPLANTATION, 32, 1153-1157, 2003.
67. Rosti G, Demirer T, Giorgi U D, Kramar A, Droz JP, Biron P, on behalf of EBMT-
STWP and IT-94 study. Advanced Germ cell tumors: The EBMT experience and the
IT-94 study. (Book Chapter) ABMT XI-Chapter 4-Solid Tumors, 2003.
68. Demirer T. The EBMT Handbook. Haemopoietic Stem Cell Transplantation.
European School of Haematology. Editors: J Apperley, A Gratwohl. Chapter 16.4 :
Solid Tumors, Page: 277, 2004.
69. Gratwohl A, Baldomero H, Demirer T, Rosti G, Dini G, Ladenstein R, Urbano-
Ispizua A. Hematopoetic Stem cell transplantation for solid tumors in Europe.
ANNALS OF ONCOLOGY, Apr; 15 (4): 653-60, 2004.
35
35
70. Demirer T, Ayli M, Fen T, Ozcan M, Arat M, Büyükberber S, Arslan Ö, Gürman,
Akan H, Ilhan O. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by
autologous peripheral blood stem cell transplantation in patients with lmphoma: A
retrospective evaluation. BONE MARROW TRANSPLANTATION, 34, 781-786, 2004.
71. Demirer T. Autologous stem cell transplantation and allogeneic non-
myeloablative transplants in solid tumors. International Journal of Hematology-
Oncology & Bone Marrow Transplantation, Vol:1, No:3, pp: 4-8, 2004.
72. Giorgi U D, Wandt H, Lioure B, Leyvraz S, Papiani G, Ballardini M, Kulekci A,
Demirer T. First-line high-dose chemotherapy for patients with poor prognosis
extragonadal germ cell tumors. The experience of the European Bone Marrow
Transplantation (EBMT) Solid Tumors Working party. BONE MARROW
TRANSPLANTATION, Dec;34 (12): 1033-1037, 2004.
73. Giorgi U De, Demirer T, Wandt H, Taverna C, Siegert W, Bornhauser M, Kozak
T, Papiani G, Ballardini M, Rosti G. Second-line high-dose chemotherapy in patients
with mediastinal and retroperitoneal primary nonseminomatous germ cell tumors: the
EBMT experience. ANNALS OF ONCOLOGY, vol: 16 , pp: 146-151, 2005.
74. Bengala C, Guarneri V, Ledermann J, Rosti G, Wandt H, Lotz JP, Cure JH,
Orlandini C, Ferrante P, Conte PF, Demirer T on behalf of EBMT Solid Tumor Working
Party. High-dose chemotherapy with autologous hemopoietic support for advanced
ovarian cancer in first complete remission: retrospective analysis from the Solid Tumor
Registry of the European Group for Blood and marrow Transplantation (EBMT). BONE
MARROW TRANSPLANT, vol 36, pp 25-31, 2005.
36
36
75. U De Giorgi, G Rosti, S Slavin, I Yaniv, J L Harousseau, R Ladenstein, T
Demirer & G Dini on behalf of the European Group for Blood & Marrow Transplantation
Solid Tumours & Paediatric Disease Working Parties. Salvage high-dose
chemotherapy for children with extragonadal germ-cell tumours. BRITISH JOURNAL
of CANCER, Volume 93, Number 4, 412-417, 2005.
76. Peccatori J, Barkholt L, Demirer T, Sormani M.P, Bruzzi P, Ciceri F, Zambelli
A, Da Prada GA, Pedrazzoli P, Siena S, Massenkeil G, Martino R, Lenhoff S,
Corradini P, Rosti G, Ringden O, Bregni M and Niederwieser D, on behalf of EBMT
Solid Tumor Working Party. Prognostic factors for survival in patients with advanced
renal cell cancer undergoing non-myeloablative allogeneic stem cell transplantation.
CANCER JOURNAL, Vol: 104, issue 10, pages, 2099-2103, 2005..
77.Ljungman P, Urbano-Ispizua A, Cavazzini-Calvo M, Demirer T, Dini G, Einsele H,
Gratwohl A, Madrigal A, Niederwieser D, Passweg J, Rocha V, Saccardi R, Schouten
H, Socie G, Sureda A, and Apperley J for the European Group for Blood and Marrow
Transplantation. Allogeneic and autologous transplantation for haematological
diseases, solid tumours and immune disorders: definitions and current practice in
Europe. BONE MARROW TRANSPLANT, 37 (5), 439-49, 2006.
78. Barkholt L, Bregni M, Remberger M, Blaise D, Peccatori J, Massenkiel G,
Pedrazzoli P, Zambelli A, Bay J. O, Francois S, Martino R, Bengala C, Brune M,
Lenhoff S, Porcellini A, Falda M, Siena S, Demirer T, Niederwieser D and Ringdén
O. On behalf of the EBMT Solid Tumour Working Party. European experience of
allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma.
ANNALS OF ONCOLOGY, Vol: 17, pp1134-1140, 2006.
37
37
79. Pedrazzoli P, Ledermann JA, Lotz JP, Leyvraz S, Aglietta M, Rosti G, Champion
K, Secondino S, Selle F, Ketterer N, Grignani G, Siena S, Demirer T, on behalf of the
EBMT Solid Tumors Working Party. High-dose chemotherapy with autologous
hematopoietic stem cell support for solid tumors other than breast cancer in adults.
ANNALS OF ONCOLOGY, Vol: 17 (10), pp 1479-1488, 2006
80. Bay JO, Linassier C, Biron P, Durando X, Verrelle P, Rosti G, Demirer T, for the
EBMT Solid Tumors Working Party. Does high-dose BCNU increase overall survival in
supratentorial high-grade malignant gliomas? An EBMT retrospective study.
INTERNATIONAL JOURNAL OF CANCER, Vol:120, issue 8, pp 1782-86, 2007
81. Secondino S, Carrabba MG, Pedrazzoli P, Castagna L, Spina F, Grosso F,
Bertuzzi A, Bay JO, Siena S, Corradini P, Niederwieser D, Demirer T. Reducued
intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a
retrospective analysis of the European Group for Blood and Marrow Transplantation.
HAEMATOLOGICA, Vol:92, pp 418-20, 2007.
82. Pedrazzoli P, Rosti G, Secondino S, Carminati O, Demirer T, on behalf of
the European Group for Blood and Marrow Trasplantation (EBMT), Solid Tumors
Working Party and Gruppo Italiano di Trapianto Midollo Osseo (GITMO). High dose
chemotherapy with autologous hematopoietic stem cell support for solid tumors in
adults. SEMINARS IN HEMATOLOGY, Vol:44, pp 286-295, 2007.
83. Giorgi UD, Blaise D, Lange A, Viens P, Marangolo M, Madroszyk A, Brune M,
Afanassiev BV, Rosti G, and Demirer T. High-dose chemotherapy with peripheral
blood progenitor cell support for patients with non-small cell lung cancer: the experience
of the European Group for Bone Marrow Transplantation (EBMT) Solid Tumours
Working Party. BONE MARROW TRANSPLANTATION, Vol: 40, pp 1045-1048, 2007.
38
38
84. Demirer T, Barkholt L, Blaise D, Pedrazzoli P, Aglietta M, Carella AM, Bay JO,
Arpacı F, Rosti G, Gurman G, Niederwieser D, Bregni M, on behalf of the EBMT Solid
Tumors Working Party. Transplantation of allogeneic hematopoietic stem cells: an
emerging treatment modality for solid tumors. NATURE CLINICAL PRACTICE
ONCOLOGY, Vol: 5, No: 5, pp 256-267, 2008.
85. İlhan O, Topçuoğlu P, Arat M, Soydan EA, Yuksel MK, Arslan Ö, Özcan M,
Gürman G, Demirer T, Akan H, Konuk N, Uysal A. Allogeneic hematopoietic stem cell
transplantation (allo-HSCT) in acute myeloblastic leukemia (AML): A single center
experience, TURK J HAEMATOL Pages 87 – 93, Vol:25, ıssue 2, 2008.
86. Ueno N T, Rizzo D, Demirer T, Cheng YC, Hegenbart U, Zhang MJ, Bregni M,
Rondon G, Champlin RE, Antman K, Stiff PJ, Horowitz MM, Niederwieser D.
Allogeneic hematopoietic cell transplantation for metastatic breast cancer. BONE
MARROW TRANSPLANT, Vol: 41, pp 537-545, 2008.
87. Ladenstein R, Pötschger U, Hartman O, Pearson ADJ, Klingebiel, Castel V,
Yaniv I, Demirer T, and Dini G, on behalf of the EBMT Paediatric Working Party. 28
years of hıgh-dose therapy and SCT for neuroblastoma in Europe: lessons from more
than 4000 procedures. BONE MARROW TRANSPLANTATION, Vol: 41, S 118-127,
2008.
88. Aglietta M, Barkholt L, Carnevale Schianca F Caravelli D, Omazic B, Minotto C,
Leone F, Hentschke P. Bertoldero G , Capaldi A, Ciccone G, Niederwieser D,
Ringdén O, Demirer T, On behalf of the EBMT Solid Tumor Working Party. Reduced
Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Colorectal
Cancer as a Novel Adoptive Cell Therapy Approach. The European Group for Blood
and Marrow Transplantation Experience. BIOLOGY of BLOOD and MARROW
TRANSPLANTATION, vol: 15, ıssue 3, pages: 326-335, 2009..
39
39
89. Aktaş B, Topcuoglu P, Kurt ÖK, Ensari A, Demirer T. Severe Henoch-Schönlein
Purpura induced by Cytarabine. THE ANNALS OF PHARMACOTHERAPY, Letter, vol:
43 (4), pp 792-3, 2009.
90. Ozcelik T, Topcuoglu P, Beksac M, Ozcan M, Arat M, Bıyıklı Z, Bakanay SM,
Ilhan O, Gurman G, Arslan O, Demirer T. Mobilization of PBSCs with chemotherapy
and recombinant human G-CSF: a randomized evaluation of early vs late administration
of recombinant human G-CSF. BONE MARROW TRANSPLANTATION, Vol: 44, No:
12, pp 779-783, 2009.
91. Bay JO, Cabrespine-Faugeras A, Tabrizi R, Blaise D, Viens P, Ehninger G,
Bornhauser M, Slavin S, Rosti G, Demirer T, Bregni M. Allogeneic stem cell
transplantation in ovarian cancer. The EBMT Experience. In Press, INT. J. CANCER.
92. DA Berry, NT Ueno, MM Johnson, X Lei, J Caputo, S Rodenhuis, WP Peters, RC
Leonard, SI Bearman, MS Tallman, J Bergh, UA Nitz, A Gianni, RL Basser, AR Zander,
RC Coombes, H Roche, Y Tokuda, JG Schrama, GN Hortobagyi, M Bregni, T.
Demirer. High dose chemotherapy with autologous stem cell support versus standard-
dose chemotherapy: Overview of individual patient data from 15 randomized adjuvant
therapy breast cancer trials. J. CLIN. ONCOL, 29 (24), pages: 3214-3223, 2011
93. DA Berry, NT Ueno, MM Johnson, X Lei, J Caputo, D Smith, L Yancey, M Crump,
EA Stadmauer, H Roche, JP Crown, P Schmid, JP Lotz, M Bregni, T. Demirer. High
dose chemotherapy with autologous hematopoietic stem cell transplantation versus
standard-dose chemotherapy: Overview of individual patient data from six randomized
metastatic breast cancer trials. J. CLIN. ONCOL, 29 (24), pages: 3224-31, 2011
40
40
94. P Pedrazzoli, P Comoli, D Montagna, T Demirer, M Bregni on behalf of the
EBMT Solid Tumors Working Party. Is adoptive T-Cell Therapy for solid tumors coming
of age? BONE MARROW TRANSPLANTATION, Vol: 47 (8), Pages: 1013-1019,
2012.
95. SM Bakanay, T Demirer. Novel agents and approaches fors tem cell
mobilization in normal donors and patients. BONE MARROW TRANSPLANTATION,
47, pages: 1154-1163, 2012.
96. Stem Cell Transplantation- An Introduction. T Demirer, Editor. Stem Cell
Transplantation. Edited by: T. Demirer, Published by Intech, 2012.
97. P Pedrazzoli, G Rosti, S Secondino, M Bregni, T Demirer, on
behalf of the European Group for Blood and Marrow Trasplantation (EBMT), Solid
Tumors Working Party. Intensified chemotherapy with stem cell support for solid
tumor in adults: 30 years of investigations can provide some clear answers?
Chapter 18, pages 371-380, Book Chapter In Stem Cell Transplantation, Edited
by: T. Demirer, Published by Intech, 2012
98. Y Koç, T Demirer. Mantle Cell Lymphoma : Decision making for transplant.
? Chapter 15, pages 319-344, Book Chapter In Stem Cell Transplantation,
Edited by T. Demirer, Published by Intech, 2012.
99. Ş.M. Bakanay, T Demirer. Stem Cell Mobilization In Multiple Myeloma. ?
Chapter 13, pages241-262, Book Chapter In Multiple Myeloma- An Overwiew,
Edited by Ajay Gupta, Published by Intech, 2012
41
41
100. T. Demirer. Response to ‘Are there still reasons to believe that high-dose
chemotherapy have a role in breast cancer management ? Letter to Editor, BONE
MARROW TRANSPLANTATION, Vol: 48, issue: 2, pp 305-6, 2013.
101. C. Soydal, E. Ozkan, M. Araz, Ö Kucuk, T. Demirer. Intense Ga-68 Dotatate
uptake in recurrent MTC patient. World Journal of Endocrine Surgery, Vol: 4(3), pp
118-119, 2012.
102. Innovations in Stem Cell Transplantation- An Introduction. T Demirer,
Editor. Innovations in Stem Cell Transplantation. Edited by: T. Demirer, Published
by Intech, pp VII-VIII, 2013.
103. L Kaynar, M. Çetin, A Ünal, T Demirer. Current Status of Hematopoietic
Stem Cell Transplatation in Patients with Refractory or Relapse Hodgkin
Lymphoma. Chapter 13, pages 289-304, Book Chapter In Innovations inStem Cell
Transplantation, Edited by T. Demirer, Published by Intech, 2013.
104. Z A Yegin, G T Sucak, T Demirer. Iron Overload and Hematopoietic Stem
Cell Transplantation. Chapter 14, pages305-329, Book Chapter In Innovations
inStem Cell Transplantation, Edited by T. Demirer, Published by Intech, 2013.
105. P. Topcuoglu, S.C. Bozdag, T Demirer. Allogeneic Hematopoietic Stem
Cell Transplantation in Multiple Myeloma. Chapter 8, pages165-177, Book
Chapter In Multiple Myeloma- A Quick reflection on the fast progress. Edited by R.
Hajek, Published by Intech, 2013.
42
42
106. P Pedrazzoli, M Bregni, G Rosti, F Lanza, T Demirer. Autologous Stem Cell
Transplantation : Is it still relevant in breast cancer. Breast Cancer Management, Vol :
2(6), pp : 447-450, 2013.
107. C. Soydal, E. Ozkan, M. Araz, Ö Kucuk, T. Demirer. Recurrent medullary
carcinoma detected by Gallium-68 positron emission tomography. World Journal of
Endocrine Surgery, Vol: 5(2), pp 59-60, 2013.
108. M. Martino, F. Lanza, M. Mohty, T. Demirer, T. Martinello, S. Secondino, P.
Pedrazzoli on behalf of the European Society for Blood and Marrow Transplantation,
Solid Tumors Working party (EBMT-STWP). Erythropoiesis-stimulating agents in
allogeneic and autologous hematopoietic stem cell transplantation. Expert Opin Biol
Ther, 15 (2): 195-211, 2015.
109. M Özen, S Bozdağ, G Çakmak, P Topçuoğlu, Ö Arslan, T Demirer, H Akan, O
İlhan, G Gürman, M Özcan. Antilymphocyte/thymocyte globulin for the treatment of
steroid-refractory acute graft-versus-host disease: 20-year experience at a single
center. International Journal of Hematology/Oncology, Pp 236-244, No: 4, Vol: 25,
2015
110. P Topcuoglu, SC Bozdag, T Demirer. Use of Monoclonal Antibodies in
Conditioning Regimenin Transplantation. Chapter 3, pp 43-56, Book Chapter, in
Progress in Stem Cell Transplantation. Edited by, T. Demirer, Published by Intech,
2015.
43
43
2016 (Yayın Yılı)
111. Mehmet Özen, Gülden Yılmaz, Belgin Coşkun, Pervin Topçuoğlu, Önder Arslan,
Muhit Özcan, Taner Demirer, Osman İlhan, Nahide Konuk, İsmail Balık, Günhan
Gürman, Hamdi Akan . A quasi-experimental study analyzing the effectiveness of
portable HEPA filters in preventing infections in hematology patients during
construction. Turkish Journal of Hematology, Vol: 33, pp 41-47, 2016
112. Demirer T. Autologous Stem Cell transplantation in breast Cancer: Is There Still
a Hope?. International Journal of Hematology/Oncology, No: 3, Vol: 26, pp 182-
187, 2016.
113. Sahin U, Toprak SK, Atilla Ataca P, Atilla E, Demirer T. An Overview of
Infectious Complications after Allogeneic Hematopoietic Stem Cell Transplantation.
Journal of Infection and Chemotherapy, Vol: 22, pp 505-514, 2016.
114. Şahin U, Atilla-Ataca P, Atilla E, Koçak ST, Demirer T. An Overview of
Hematopoietic Stem Cell Transplantation Related Thrombotic Complications. Critical
Reviews in Oncology/Hematology, Vol: 107, pp 149-155, 2016.
115. Karadurmuş N, Arpacı F, Şahin U, Demirer T. A Review of Allogeneic
Hematopoietic Stem Cell Transplantation With Reducued Intensity Conditioning in Solid
Tumors Other Than Breast Cancer. World Journal of Transplantation, Vol: 6(4), pp
675-681, 2016.
116) Ataca P, Atilla E, Toprak SK, Demirer T. Non-Infectious Early Complications of
Allogeneic Stem Cell Transplantations. International Journal of
Hematology/Oncology, Vol: 26, No: 4, pp 239-250, 2016.
44
44
2017 (Yayın Yılı)
117. Atilla E, Atilla Ataca P, Demirer T. A Review of Myeloablative vs Reduced
Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell
Transplantations. Balkan Med J, Vol: 34, No: 1, pp 1-9, 2017.
118. Atilla E, Toprak S. Koçak, Demirer T. Current Review of Iron Overload and
Related Complications In Hematopoietic Stem Cell Transplantation. Turkish Journal of
Hematology, Vol: 34, pp 1-9, 2017.
119. M Ö zen, C Ustun, P Topcuoglu, M Arat, M Gundu z, E Atilla, O Arslan, T
Demirer, H Akan, O lhan, M Beksac , N Konuk, G Gurman. Comparison of Allogeneic
Stem Cell Transplantation in Chronic Myeloid Leukemia And the Effect of Thyrosine
kinase inhibitors on survival. A Quasi-experimental study. Turkish Journal of
Hematology, 34 (1), pp 1-9, 2017.
120. Atilla E, Atilla Ataca P, Demirer T. Current Treatment Strategies in
Relapsed/Refractory Mantle Cell Lymphoma: Where are we now? International
Journal of Hematology, Vol:105, pp 257-264, 2017.
121. Karadurmuş N, Şahin U, Arpacı F, Demirer T. An Overview of High Dose
Chemotherapy With Autologous Stem Cell Rescue For Germ Cell Tumors In Current
Practice. Balkan Union of Oncology, Vol: 22 (2), pp 306-311, 2017 .
122. Atilla Ataca P, Ozturk Sule Mine, Demirer T. How to manage poor mobilizers for
High Dose Chemotherapy and Autologous Stem Cell Transplantation ?. Transfusion
and Apheresis Science, Vol: 56, ıssue:2, pp 190-198, 2017.
45
45
123. Atilla E, Atilla Ataca P, Toprak SK, Demirer T. A Review of Late Complications
of Allogeneic Hematopoietic Stem Cell Transplantations. Clinical Transplantation,
Vol: 31, No: 10, pp: , 2017.
124. Atilla Ataca P, Atilla E, Bozdağ SC, Demirer T. A Review of Infectious
Complications After Haploidentical Hematopoietic Stem Cell Transplantations.
Infection, 45:403-411, 2017.
125. Gündüz M, Sahin U, Toprak SK, Bozdag SC, Yuksel MK, Arslan O, Özcan M,
Demirer T, Beksac M, Ilhan O, Gurman G, Topcuoglu P. Subsequent Malignancies
After Allogeneic Hematopoietic Stem Cell Transplantation. Clinical Transplantation,
Vol: 31, No: 7, 2017.
126. Atilla E, Civriz Bozdag S, Kurt M, Toprak S, Topcuoglu P, Demirer T, Ilhan O,
Arslan O, Gurma G, Ozcan M. Treatment with methotrexate, rituximab and cytosine-
arabinoside followed by autologous stem cell transplantation in primary CNS
lymphoma: A single center experience. Accepted in Hematology/Oncology and Stem
Cell Therapy.
127. Demirer T. Preface. In Haploidentical Stem Cell Transplantation: An Emerging
Treatment Modality. Edited by Taner DEMİRER. Published by Humana Press, Springer
International Publishing, 2017.
128. Yüksel M K, Demirer T. Toxicity of Conditioning Regimens in Haploidentical
Stem Cell Transplantation. In Haploidentical Stem Cell Transplantation: An Emerging
Treatment Modality. Edited by Taner DEMİRER. Published by Humana Press, Springer
International Publishing, Chapter 4, pages 43-56, 2017.
46
46
129. Sahin U, Demirer T. Future Perspectives for Haploidentical Stem Cell
Transplantation. In Haploidentical Stem Cell Transplantation: An Emerging Treatment
Modality. Edited by Taner DEMİRER. Published by Humana Press, Springer
International Publishing, Chapter 13, pages 189-199, 2017.
130. Atilla E, Atilla PA, Bozdag SC, Yuksel MK, Toprak SK, Topcuoglu P, Akay BN,
Sanli H , Akan H, Demirer T, et al. Extracorporeal photochemotherapy in mycosis
fungoides. TRANSFUSION CLINIQUE ET BIOLOGIQUE, Volume: 24,Issue: 4,Pages:
454-457, 2017.
2018 Yayın Yılı
131. Karadurmus N, Basgöz BB, Sahin U, Demirer T. Is there a role of high dose
chemotherapy and autologous stem cell transplantation in the treatment of Ewing's
sarcoma and osteosarcomas? Balkan Union of Oncology, Vol: 23, No: 5, pp 1235-
1241, 2018.
132. Seval Cengiz G, Topcuoglu P, Demirer T. Current Approach to Non-Infectious
Pulmonary Complications of Hematopoietic Stem Cell Transplantation. Balkan Med J,
Vol: 35, No: 2, pp 131-40, 2018.
133. Karadurmus N, Sahin U, Arpaci F, Demirer T. A review of allogeneic
hematopoietic stem cell transplantation in patients with metastatic breast cancer. Int. J
of Hemat/Oncology and Stem Cell Research, Vol : 12, No : 2, pp 111-116, 2018.
47
47
134. Sahin U, Demirer T. Current strategies for the management of autologous
peripheral blood stem cell mobilization failures in patients with multiple myeloma.
Journal of Clinical Apheresis, Vol : 33, No :3, pages 357-370, 2018.
135. Bozdağ SC, Kurt MY, Demirer T. Adult Stem Cells. Advances in Experimental
Medicine and Biology, vol : 1079, pp 17-36, 2018.
136. Uckun FM, Qazi S, Demirer T, Champlin RE. Contemporary Patient-Tailored
Treatment Strategies Against High Risk and Relapsed or Refractory Multiple Myeloma.
In Press, EBioMedicine.
137. Atilla E, Atilla Ataca P, Seval GC, Bektaş M, Demirer T. Current approach to
early gastrointestinal and liver complications of hematopoietic stem cell transplantation.
In Press, Turk J Gastroenterol.
BOOKS
1. EBMT Solid Tumors Working Party and Registry. 2001 Activity Report. Edited
by: Demirer T and Kulekci A.N. Ankara University Press, Total pages: 166, February
2002.
2. EBMT Solid Tumors Working Party and Registry. 2002 Activity Report. Edited
by: Demirer T and Kulekci A.N. Ankara University Press, Total pages: 160, January
2003.
48
48
3. EBMT Solid Tumors Working Party and Registry. 2003 Activity Report. Edited
by: Demirer T and Kulekci A.N. Ankara University Press, Total pages: 52, February
2004.
EDITORSHIP 1. Stem Cell Transplantation. Edited by: Taner Demirer. Published by InTech
Company, total pages 582, 2012.
2. Innovations in Stem Cell Transplantation. Edited by: Taner Demirer.Published
by InTech Company, total pages 370, 2013.
3. A Report of National Stem Cell Policies in Turkey. Published by The Turkish
Academy of Sciences. Edited by: Alp Can and Taner Demirer, total pages 53,
2014.
4. A Report of National Cancer Policies in Turkey. Published by The Turkish
Academy of Sciences. Edited by: Taner Demirer, Nur Olgun and Ahmet Özet,
total pages 93, 2014.
5. A Report of problems experienced in related to coordination during treatment of
cancer patients in Turkey. Published by The Turkish Academy of Sciences.
Edited by: Taner Demirer, total pages 93, 2014.
6. A report of Nutrition and Cancer. Published by The Turkish Academy of
49
49
Sciences. Edited by: Taner Demirer, total pages 155, 2015.
7. Progress in Stem Cell Transplantation. Edited by: Taner Demirer. Published by
InTech Company, total pages 197, 2015.
8. Haploidentical Stem Cell Transplantation: An Emerging Treatment Modality.
Edited by Taner DEMİRER. Published by Humana Press, Springer International
Publishing, total pages 200, 2017.
9. TÜBA A report of phase studies in Clinical research . Edited by: Taner
DEMİRER, Total pages: 120 , January 2017.
10. TÜBA Food Safety Symposium Edited by: Taner DEMİRER, total pages 148,
October 2017.
50
50
ABSTRACTS
1. Kucuk O, Demirer T, Gilman-Sachs A, Westerman M.P. et al: Correlation of
DNA ploidy with stage and histology in prostate cancer patients. Proceedings of the
American Association for Cancer Research, Volume 32, Abs. No:160, March 1991.
2. Demirer T, Buckner C.D, Petersen F.B, Appelbaum F, Rowley S, Lilleby K,
Sanders J, Chauncey T, Storb R, Benyunes MC, Fefer A, and Bensinger W.: Rapid
engraftment after autologous transplantation utilizing marrow and recombinant
granulocyte-colony stimulating factor (G-CSF) mobilized peripheral blood stem cells in
patients with acute myelogenous leukemia (AML). "BLOOD" Vol:84, No:10, Suppl 1,
pp 92a, Abstr:356, 1994.
3. Demirer T, Gooley T, Buckner CD, Petersen FB, Lilleby K, Rowley S, Sanders J,
Storb R, Appelbaum FR, Bensinger WI: The influence of total nucleated cell dose from
marrow harvests on outcome in patients with acute myelogenous leukemia undergoing
autologous transplantation. "BLOOD" Vol:84, No:10, Suppl 1, pp 348a, Abstr:1376,
1994.
4. Demirer T, Bensinger WI, Rowley S, Appelbaum FR, Petersen FB, Chauncey T,
51
51
Fefer A, Buckner CD: Comparison of granulocyte-colony stimulating factor mobilized
peripheral blood stem cells and bone marrow for autologous transplantation in patients
with acute myelogenous leukemia. "BLOOD" Vol:86, No:10, Suppl 1, pp 99a,
Abstr:381, 1995.
5. Demirer T, Bensinger WI, Appelbaum FR, Rowley S, Buckner CD: Autologous
stem cell transplantation for patients with multiple myeloma. "BLOOD" Vol:86, No:10,
Suppl 1, pp 207a, Abstr:815, 1995.
6. Chauncey TR, Gooley TA, Appelbaum FR, Demirer T, Holmberg L, Lilleby K,
Rowley SD, Buckner CD: Quantitative CD34 collection does not independently predict
clinical outcome after autologous PBSC transplantation. "BLOOD" Vol:86, No: 10,
Suppl 1, pp 941a, Abstr: 3751, 1995.
7. Demirer T, Buckner CD, Storer B, Rowley S, Schiffman K, Bensinger WI: The
effect of different chemotherapy regimens on peripheral blood stem cell mobilization
yield. ASCO proceedings. Vol:15, P:345, Abstr:1007, 1996.
8. Holmberg L.A, Demirer T, Schiffman K, Rowley SD, Buckner CD, Goodman G,
Maziarz R, Appelbaum FR, and Bensinger WI: High-dose busulfan, melphalan, and
thiotepa (BUMELTT) followed by autologous peripheral blood stem cells (PBSC) rescue
in patients with advanced stage III/IV ovarian cancer. “BLOOD” , Vol:90, No:10, Suppl
1(part 1 of 2) abstr:1705, 1997.
9. Arat M, Üstün C, Arslan Ö, Ayyıldız E, Koç H, Beksaç M, Akan H, Gürman G,
Özcan M, Demirer T, Uysal A, Konuk N, İlhan O: Correlation of CD34+ mononuclear
cells and engraftment time in allogeneic peripheral blood stem cell transplantation.
Boletim da Sociedade Brasileira de Hematologia a hemoterapia (VII International
Congress of the World Apheresis Association-WAA), Abstract C 75, pp 176, Volume
52
52
XX-Suplemento Outubro 1998, ISSN 0102-7662.
10. M. Özcan, C. Üstün, O. İlhan, M. Beksaç, E. Akçağlayan, G. Gürman, H. Akan,
T. Demirer, M. Arat, H. Çelebi, N. Konuk, A. Uysal. The effect of G-CSF in the first 100
days of allogeneic peripheral blood stem cell transplantation. BLOOD Vol:92, No:10,
Suppl 1 (part 2 of 2), abstr:4405, pp 326b, 1998.
11. G. Gürman, C. Üstün, Ö. Arslan, M. Beksaç, N. Konuk, M. Arat, H. Çelebi, M.
Özcan, O İlhan, T. Demirer, H. Akan, A. Uysal, H. Koç. Allogeneic hematopoietic
stem cell transplantation in patients with advanced hematological malignancies by using
non-myeloablative conditioning regimen. BLOOD Vol:92, No:10, Suppl 1 (part 2 of 2),
abstr:4509, pp 350b, 1998.
12. C. Üstün, M. Özcan, M. Beksaç, O İlhan, M. Çakır, G. Gürman, H. Akan, T.
Demirer, M. Arat, H. Çelebi, N. Konuk, A. Uysal. Clinical effects of intravenous immüne
globulin (IVIG) treatment in patients with allogeneic peripheral stem cell transplantation.
BLOOD Vol:92, No:10, Suppl 1 (part 2 of 2), abstr:4528, pp 355b, 1998.
13. Üstün C, İdilman R, Özcan M, Akan H, Karayalçın S, Gürman G, İlhan O, Beksaç
M, Uysal A, Konuk N, Demirer T, Koç H. Which hematopoietic stem cell
transplantation type is safe for patients with hepatitis B virus carriers. HEPATOLOGY
vol: 28, No 4, S, pp 2221, 1998.
14. Gürman G, Üstün C, Arslan Ö, Beksaç M, Konuk N, Arat M, Çelebi H, Özcan M,
İlhan O, Demirer T, Akan H, Uysal A, Koç H: Allogeneic hematopoietic cell
transplantation in patients with advanced hematological malignancies by using non-
myeloablative conditioning regimen. BONE MARROW TRANSPLANTATION, Vol:23,
53
53
Suppl 1, abstr:70, S22, 1999.
15. Üstün C, Özcan M, Beksaç M, İlhan O, Çakır M, Gürman G, Arslan Ö, Akan H,
Demirer T, Arat M, Çelebi H, Konuk N, Uysal A, Koç H: Clinical effects of intravenous
immune gloguline (IVIG) treatment in patients with allogeneic peripheral stem cell
transplantation. BONE MARROW TRANSPLANTATION, Vol:23, Suppl 1, abstr:567,
S171, 1999.
16. Demirer T, Arat M, Koç H, İlhan O, Çelebi H, Özcan M, Akan H, Gürman G,
Uysal A: A protocol proposal comparing conventional approach with high-dose
chemotherapy (HDC) and peripheral blood stem cell transplantation (PBSCT) in
patients with small cell lung cancer limited to thorax. BONE MARROW
TRANSPLANTATION, Vol:23, Suppl 1, abstr:625, S189, 1999.
17. Demirer T, Arat M, Koç H, İlhan O, Akan H, Gürman G, Özcan M, Çelebi H,
Üstün C, Uysal A: A protocol proposal for high-dose chemotherapy (HDC) with
autologous peripheral blood stem cell transplantation (PBSCT) versus conventional
chemotherapy in patients with relapsed cisplatin sensitive epithelial ovarian cancer-2
arm randomized study. BONE MARROW TRANSPLANTATION, Vol:23, Suppl 1,
abstr:626, S189, 1999
18. Ilhan O, Demirer T, Arat M, Dalva K, Coşkun Ş, Beksaç M, Akan H, Özcan M,
Arslan Ö, Gürman G, Koç H: The influence of CD41+ and CD42+ peripheral blood stem
cells on platelet engraftment after allo PBSCT. BONE MARROW
TRANSPLANTATION, Vol:23, Suppl 1, abstr:672, S201, 1999
19. Özcan M, Üstün C, İlhan O, Beksaç M, Akçağlayan E, Gürman G, Akan H,
Demirer T, Arat M, Çelebi H, Konuk N, Uysal A, Koç H: The effect of G-CSF in the first
54
54
100 days of allogeneic peripheral blood stem cell transplantation. BONE MARROW
TRANSPLANTATION, Vol:23, Suppl 1, abstr:688, S205, 1999
20. Arat M, Demirer T, Ilhan O, koç H, Üstün C, Çelebi H, Ayyıldız E, Tüzün A,
Gürman G, Özcan M: Peripheral blood stem cell (PBSC) collection with
cyclophosphamide (CY) – paclitaxel and recombinant human granulocyte-colony
stimulating factor (rhG-CSF) in patients with breast cancer: Ibn-i Sina experience.
BONE MARROW TRANSPLANTATION, Vol:23, Suppl 1, abstr:713, S212, 1999
21. Arat M, Demirer T, Üstün C, Çelebi H, Tüzün A, Coşkun Ş, Ayyıldız E, İlhan O,
Gürman G, Özcan M, Koç H. A phase I dose escalation study of high dose thiotepa,
melphalan and carboplatin in patients with high risk breast cancer and hematologic
malignancies. Proceedings of ASCO Vol:18, abstract 207, pp 56a, 1999.
22. Beksaç M, Akan H, Koç H, İlhan O, Uysal A, Özcan M, Demirer T, Konuk N et
al: Comparison of allogeneic peripheral blood stem cell transplantation: A prospective
randomized EBMT study. Results of Ankara University. Turk J Haematol, 16, 3 (suppl
1): abstr 40, pp 138, 1999.
23. Özcan M, Üstün C, İlhan O, Beksaç M, Akçağlayan E, Arslan Ö, Gürman G,
Akan H, Demirer T, et al: The effect of G-CSF in the first 100 days of allogeneic
peripheral blood stem cell transplantation. Turk J Haematol, 16, 3 (suppl 1): abstr 43,
pp 140, 1999.
24. Demirer T, İlhan O, Mandel NM, Arat M, Çelebi HA phase I dose escalation
study of high-dose thiotepa, melphalan, and carboplatin (TMCb) followed by autologous
peripheral blood stem cell (PBSC) transplantation in patients with solid tumors and
hematologic malignancies. Turk J Haematol, 16, 3 (suppl 1): abstr 44, pp 140, 1999.
25. Arslan Ö, Coşkun HŞ, Üstün C, Arat M, Çelebi H, Özcan M, Gürman G, Akan H,
55
55
İlhan O, Konuk N, Demirer T, et al: Experience of ibn-I sina hospital in allogeneic
peripheral blood stem cell transplantation for standard risk leukemia patients. Turk J
Haematol, 16, 3 (suppl 1): abstr 46, pp 141, 1999
26. Üstün C, Özcan M, Beksaç M, İlhan O, Çakır M, Gürman G, Arslan Ö, Akan H,
Demirer T, et al: Clinical effects of intravenous immune globuline (IVIG) treatment in
patients with allogeneic peripheral blood stem cell transplantation. Turk J Haematol,
16, 3 (suppl 1): abstr 49, pp 143, 1999
27. Gürman G, Üstün C, Arslan Ö, Beksaç M, konuk N, Arat M, Çelebi H, Özcan M,
İlhan O, Demirer T et al: Allogeneic hematopoietic cell transplantation in patients with
advanced hematological malignancies by using nonmyeloablative conditioning regimen.
Turk J Haematol, 16, 3 (suppl 1): abstr 50, pp 143, 1999
28. Ilhan O, Demirer T, Arat M, Dalva K, Coşkun HŞ, et al: The influence of CD41+
and CD42+ peripheral blood stem cells on platelet engraftment after allo PBSCT.
Turk J Haematol, 16, 3 (suppl 1): abstr 51, pp 144, 1999
29. Arslan Ö, Arat M, İlhan O, Ayyıldız E, Üstün C, Çelebi H, Tekin M, Özcan M,
Gürman G, Demirer T et al: The influence of donors peripheral blood CD34+ cells on
collection and engraftment kinetics in allogeneic peripheral blood stem cell
transplantation. Turk J Haematol, 16, 3 (suppl 1): abstr 52, pp 144, 1999
30. Arslan Ö, Coşkun HŞ, Akçağlayan E, Özcan M, Gürman G, Arat M, Çelebi H,
Demirer T, et al: Comparison of ABO/Rh blood group incompatible and compatible
patients in allogeneic peripheral blood stem cell transplantation. Turk J Haematol, 16,
3 (suppl 1): abstr 53, pp 145, 1999
31. Arslan Ö, Arat M, Üstün C, Çelebi H, Özcan M, Gürman G, Tekin M, Ayyıldız E,
Demirer T et al: The influence ofdonors peripheral blood CD34+ cells on collection and
56
56
engraftment kinetics in allogeneic peripheral blood stem cell transplantation. Turk J
Haematol, 16, 3 (suppl 1): abstr 55, pp 146, 1999
32. Arat M, Arslan Ö, Ayyıldız E, Akan H, Koç H, Özcan M, Gürman G, Demirer T et
al: CD34 positive stem cell selection with isolex 300I: The first live procedure in Turkey.
Turk J Haematol, 16, 3 (suppl 1): abstr 56, pp 146, 1999
33. Özcan M, Çelebi H, Gürman G, Arslan Ö, Demirer T et al: Treatment of
refractory AGVHD with anti-thymocyte globulin. Turk J Haematol, 16, 3 (suppl 1): abstr
57, pp 147, 1999
34. İlhan O, Demirer T, Arat M, Arslan Ö, Dalva K, et al: Platelet engraftment after
allo PBSCT: the role of CD41+ and CD42+ stem cells. Haematologica, vol:84, EHA-4
Abstr book, abstr PO-0282, pp 66, 1999.
35. Arslan Ö, Coşkun HŞ, Üstün C, Arat M, Çelebi H, Özcan M, Gürman G, Akan H,
İlhan O, Konuk N, Demirer T et al: Experience of Ibn-I Sina Hospital in allogeneic
peripheral blood stem cell transplantation for standar risk leukemia patients.
Haematologica, vol:84, EHA-4 Abstr book, abstr PO-0283, pp 66, 1999.
36. Demirer T, Ilhan O, Arat M, Günel N, Çelebi H, Özcan M, Gürman G, Akan H,
Uysal A, Koç H. A phase I dose escalatıon study of high dose thiotepa, melphalan, and
carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation
(PBSCT) in patients with solid tumors and hematologic malignancies. Bone Marrow
Transplantation, vol 25, suppl 1, abstr P905, page S279.
37. Aylı M, Çelik Z, Oymak A, Fen T, Tekin K, Eser N, Demirer T. Mobilization of
hematopoietic progenitor cells with paclitaxel, cyclophosphamide (CY) and recombinant
57
57
human granulocyte-colony stimulating factor (rh-GCSF) in patients with lymphoid
malignancies and breast cancer. The Hematology Journal, Vol 1, suppl 1, abstr 743,
pp 190, 2000.
38. Aylı M, Fen T, Demirer A, Çelik Z, Oymak A, Özdel Ö, Demirer T. CD34+ PBSC
mobilization with cyclophosphamide (CY), paclitaxel and recombinant human
granulocyte colony stimulating factor (Rh-GCSF) in patients with lymphoid
malignancies. Annals of Oncology, Vol 11, Suppl 4, 439P, 2000.
39. Demirer T, Aylı M, Demirer A et al. Peripheral blood stem cell (PBSC)
collection with cyclophosphamide (CY), etoposide and recombinant human granulocyte-
colony stimulating factor (rhG-CSF) in patients with hematologic malignancies and solid
tumors. BLOOD, Vol: 96, No: 11 (part 1 of 2 parts), abstract: 5105, pp 314b, 2000.
40. Demirer T, Aylı M, Demirer A, et al. Peripheral blood stem cell (PBSC)
collection with cyclophosphamide (CY), epirubicin and recombinant human granulocyte-
colony stimulating factor (rhG-CSF) in patients with breast and ovarian cancer.
BLOOD, Vol: 96, No: 11 (part 1 of 2 parts), abstract: 5106, pp 315b, 2000.
41. Ilhan O, Arslan Ö, Arat M, Özcan M, Gürman G, Dalva K, Beksaç M, Demirer T
et al. The value of peripheral blood CD34+ cell quantitation in autologous
hematopoietic stem cell apheresis. BLOOD, Vol: 96, No: 11 (part 1 of 2 parts),
abstract: 5111, pp 316b, 2000.
42. Demirer T, Ilhan O, Aylı M, et al. Phase-II study of high-dose thiotepa,
melphalan, and carboplatin (TMCb) with autologous peripheral blood stem cell (PBSC)
support in patients with hematologic malignancies and solid tumors. BLOOD, Vol: 96,
No: 11 (part 1 of 2 parts), abstract: 5344, pp 368b, 2000.
43. Demirer T, Ilhan O, Aylı M, Arat M, Fen T et al. High-dose thiotepa, melphalan
58
58
and carboplatin (TMCb) with autologous peripheral blood stem cell (PBSC) support in
patients with hematologic malignancies and solid tumors. Bone Marrow
Transplantation, Vol:27, Suppl 1, EBMT 2001.
44. Demirer T, Ilhan O, Aylı M, et al. Cyclophosphamide (CY), etoposide (E) and
granulocyte-colony stimulating factor (G-CSF) for the collection of peripheral blood stem
cells. ASCO Proceedings, Abstract 67, pp 18a, Poster presentation, 2001.
45. Demirer T, Aylı M, Ilhan O, et al: Peripheral blood stem cell (PBSC) collection
with cyclophosphamide (CY), etoposide (E) and granulocyte-colony stimulating factor :
The effect of preleukapheresis circulating (PLC) CD34 cells on the yield. The
Hematology Journal, Volume-I, Suppl 1, Poster 761, 2001.
46. Demirer T, Aylı M, Günel N, et al: A randomized study of comparison of
leukapheresis volumes 8 L versus 10 L. The Hematology Journal, Volume-I, Suppl 1,
Abstract 768, 2001.
47. Arat M, Arslan Ö, Özcan M, Gürman G, Beksaç M, Koç H, Ayyıldız E, Topçuolu
P, Dalva K, Demirer T, Uysal A, Konuk N, Ilhan O. Allogeneic peripheral blood stem
cell apheresis : Ibn-i sina experience. XIII Congress of the European Society for
Haemapheresis. Rıva del Garda, Italy, page 64, 2001, Oral presentation.
48. Demirer T, Aylı M, Günel N et al. A randomized trial of assessment of efficacy
of leukapheresis volumes, 8 L versus 10 L. XIII Congress of the European Society
for Haemapheresis. Rıva del Garda, Italy, page 67, 2001, Oral presentation.
49. Arat M, Arslan Ö, Ayyıldız E, Çitçi A, Demirer T, Ilhan O. Stem cell mobilization
with cyclophosphamide (CY) based regimen in multiple myeloma: Ibn-i Sina
59
59
Experience. XIII Congress of the European Society for Haemapheresis. Rıva del
Garda, Italy, Poster, page 171, 2001.
50. Arslan Ö, Arat M, Ozcan M, Gürman G, Koç H, Ahan H, Demirer T et al.
Autologous peripheral blood stem cell mobilization: Ibn-i Sina Experience. XIII
Congress of the European Society for Haemapheresis. Rıva del Garda, Italy,
Poster, page 174, 2001.
51. Demirer T, Aylı M, Ozcan M, et al: Mobilization of peripheral blood stem cells
with chemotherapy and recombinant human granulocyte colony stimulating factor (rhG-
CSF): A randomized evaluation of different doses of Rh-GCSF. XIII Congress of the
European Society for Haemapheresis. Rıva del Garda, Italy, Poster, page 184, 2001.
52. Ilhan O, Arat M, Arslan O, Ozcan M, Gürman G, Demirer T, Konuk N, Uysal A,
Akan H: Evaluation of Mobilization efficiency of cyclophosphamide (CY) based regimen
by peripheral blood CD34+ cell quantification. XIII Congress of the European Society
for Haemapheresis. Rıva del Garda, Italy, Poster, page 192, 2001.
53. Bengala C, Guarneri V, Ledermann J, Wandt H, Lotz J, Cure J, Rosti G,
Ferrante P, Demirer T, Conte P on behalf of the Solid Tumour Working Party of the
EBMT. High-dose chemotherapy with autologous hemopoietic support for advanced
ovarian cancer in 1st complete remission: retrospective analysis from Solid Tumor
Registry of the European Group for Blood and Marrow Transplantation. Bone Marrow
Transplantation, Vol 29, Suppl 2, S 32, abstr 200 , 2002, (Oral Presentation).
54. Demirer T. The EBMT Solid Tumours Working Party (STWP) Registry: 2001
report. Bone Marrow Transplantation, Vol 29, Suppl 2, S 189, abstr 702 (Poster
presentation), 2002.
60
60
55. Demirer T, Aylı M, Ozcan M,et al. Mobilization of peripheral blood stem cells
with chemotherapy and granulocyte-colony stimulating factor (G-CSF): A randomized
evaluation of different doses of G-CSF. Bone Marrow Transplantation, Vol 29, Suppl
2, S 193, abstr 713 (Poster presentation), 2002.
56. Demirer T, Aylı M, Daglı M, et al. Influence of post-transplant granulocyte-
colony stimulating factor (G-CSF) administration on peritransplant morbidity in patients
undergoing autologous stem cell transplantation. Bone Marrow Transplantation, Vol
29, Suppl 2, S 197, abstr , 2002.
57. Arslan O, Arat M, Soydan E, Coskun HS, Topcuoglu P, Ozcan M, Gurman G,
Demirer T et al. Does donor recipient ABO-incompatibility have any effect on the
course and outcome of allogeneic hematopoietic stem cell transplantation? Bone
Marrow Transplantation, Vol 29, Suppl 2, S 214, abstr 771 (Poster presentation),
2002.
58. Kröger N, Zander AR, Ferrante P, Martinelli G, Janvier M, Moraleda J, Cellerino
G, Zambelli A, Blaise D, Demirer T, Rosti G on behalf of the EBMT Working Party on
Solid Tumors. Low incidence of secondary myelodysplasia (sMDS) and acute leukemia
(sAML) after high-dose chemotherapy as adjuvant therapy for breast cancer patients.
Bone Marrow Transplantation, Vol 29, Suppl 2, S 220, abstr 788 (Poster
presentation), 2002.
59. Demirer T, Aylı M, Daglı M,et al. Mobilization of peripheral blood stem cells with
chemotherapy and granulocyte-colony stimulating factor (G-CSF): A randomized
evaluation of different doses of G-CSF. ASCO Proceedings, Vol: 21, Part 1 0f 2,
Poster discussion, Abstr 1667, page 417a, 2002.
61
61
60. Aylı M, Demirer T, Aylı M, Daglı M, et al. Influence of post-transplant
granulocyte-colony stimulating factor (G-CSF) administration on peritransplant morbidity
in patients undergoing autologous stem cell transplantation. ASCO Proceedings, Vol:
21, Part 1 0f 2, Poster , Abstr 1690, page 423a, 2002.
61. Kröger N, Zander AR, Ferrante P, Martinelli G, Janvier M, Moraleda J, Cellerino
G, Zambelli A, Blaise D, Demirer T, Rosti G on behalf of the EBMT Working Party on
Solid Tumors. Incidence of secondary myelodysplasia (sMDS) and acute leukemia
(sAML) after high-dose chemotherapy as adjuvant therapy for breast cancer patients.
ASCO Proceedings, Vol: 21, Part 2 0f 2, Abstr 2035, page 56b, 2002.
62. Demirer T, Genc Y, Ayli M, et al. Influence of post-transplant granulocyte-colony
stimulating factor (G-CSF) administration on peritransplant morbidity in patients
undergoing autologous stem cell transplantation. The Hematology Journal, Vol: 3,
Suppl 1, abstr: 84 (Poster presentation), pp 37, June 2002.
63. Demirer T, Ayli M, Dagli M, et al. The effect of post-transplant spironolactone
administration on daily potassium requirements in patients undergoing autologous stem
cell transplantation. The Hematology Journal, Vol: 3, Suppl 1, abstr: 83 (Poster
presentation), pp 37, June 2002.
64. Demirer T. CD34+ cells in the field of hematopoietic stem cell transplantation.
IXth International Symposium on Biomedical Science and Technology, BIOMED 2002,
Abstr: I-14, pp:017, (Oral Presentation) .
65. Demirer T. The EBMT Solid Tumors Working Party (STWP) registry: 2001
report. 2nd International Congress on advances in Hematology-Oncology and
62
62
BMT, Tehran, IRAN, September 25-29, pp:14, 2002, (Oral Presentation).
66. Demirer T. High-dose chemotherapy (HDC) in the adjuvant setting in patients
with high risk primary breast cancer. . 2nd International Congress on advances in
Hematology-Oncology and BMT, Tehran, IRAN, September 25-29, pp:25, 2002,
(Oral Presentation).
67. Aylı M, Demirer T, Konuk N, et al. Influence of post-transplant recombinant
human granulocyte colony stimulating factor (RhG-CSF) administration on
peritransplant morbidity in patients undergoing autologous stem cell transplantation.
Annals of Oncology, Vol:13, Supplement 5, pp 30, 2002.
68. Demirer T, Uysal A, Ayli M, et al. High dose thiotepa, melphalan and carboplatin
followed by autologous stem cell transplantation in patients with advanced breast
cancer. A retrospective evaluation. Annals of Oncology, Vol: 13, Supplement 5,
Poster 205, pp 57, 2002.
69. Rosti G, De Giorgio U, Papiani G, Wandt H, Siegert W, Kozak T, Bornhauser M,
Kulekci A, Demirer T. High-dose chemotherapy in extragonadal germ cell tumor: first
results of the EBMT registry. Bone Marrow Transplantation, Vol: 31, Suppl:1, pp:
S35, abstract: 0272, 2003, (Oral Presentation).
70. Bregni M, Peccatori J, Bernardi M, Pedrazzoli P, Siena S, Aglietta M, Slavin S,
Blaise D, Demirer T, Niederwieser D, Bay JO. Allogeneic stem cell transplantation in
ovarian cancer: the EBMT experience. Bone Marrow Transplantation, Vol: 31,
Suppl:1, pp: S36, abstract: 0275, 2003, (Oral Presentation).
71. Kröger N, Damon L, Zander A, Wandt H, Derigs G, Ferrante P, Demirer T, Rosti
63
63
G on behalf of the EBMT Solid Tumors Working Party. Secondary acute leukemia
following mitoxantronebased high-dose chemotherapy for primary breast cancer. Bone
Marrow Transplantation, Vol: 31, Suppl:1, pp: S193, Poster abstract: P687, 2003.
72. Demirer T, Ayli M, İlhan O, Koc H, Dagli M, Arat M, Fen T, Dincer S, Ozet G,
Akan H, Uysal A. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by
autologous stem cell transplantation in patients with advanced breast cancer: a
retrospective evaluation. Bone Marrow Transplantation, Vol: 31, Suppl:1, pp: S195,
Poster abstract: P695, 2003.
73. Demirer T, Ledermann J, Leyvraz S, Niederwieser D, Blaise D, Aglietta M,
Ueno N, Rosti G. The Status of bone marrow transplant clinical trials (Teaching
lecture). European Journal of Cancer. Vol: 1, No:5, pp 14, 2003.
74. Bregni M, Barkholt L, Peccatori J, Pedrazzoli P, Remberger M, Carminati O,
Ciceri F, Siena S, Martino R, Sierra J, Brune M, Bekassy AN, Corradini P, Rosti G,
Demirer T, Ringden O, Niederwieser D. Graft versus tumor effect following reduced-
intensity allogeneic stem cell transplantation in renal cell cancer . On behalf of the
EBMT Solid Tumors Working party. BLOOD, Vol: 102, No:11, part 1, pp 198a, abstract
692, 2003 (Oral presentation).
75. Barkholt L, Bregni M, Peccatori J, Pedrazzoli P, Remberger M, Carminati O,
Ciceri F, Siena J, Martino R, Sierra J, Bruness M, Lenhoff S, Corradini P, Rosti G,
Demirer T, Niederwieser D, Ringden O, on behalf od EBMT Solid Tumors Working
Party. Graft versus tumor effect following reduced intensity allogeneic stem cell
transplantation in renal cell cancer. Bone Marrow Transplantation, Vol:33, Suppl 1,
64
64
abstract 97, S4, 2004, (Oral Presentation).
76. Rosti G, Papiani G, Wandt H, Leyvraz S, Demirer T, Giorgi U De on behalf of
EBMT Solid Tumors Working Party. Early high dose chemotherapy for adult patients
with extragonadal non-seminomatouse germ cell tumors of the mediastinum and
retroperitoneum. Bone Marrow Transplantation, Vol:33, Suppl 1, abstract 265, S39,
2004, (Oral Presentation).
77. Giorgi U De, Rosti G, Slavin S, Yaniv I, Harousseau JL, Tobler A, Ladenstein R,
Demirer T, Dini G on behalf of the Solid Tumors and Paediatric Diseases Working
Parties. Long-term follow up after high-dose chemotherapy for paediatric patients with
extragonadal germ cell tumors. Bone Marrow Transplantation, Vol:33, Suppl 1,
abstract 268, S40, 2004, (Oral Presentation).
78. Demirer T, Soydan E, Fen T et al. High-dose thiotepa, melphalan, and
carboplatin followed by autologous peripheral blood stem cell transplantation in patients
with lymphoma- a retrospective evaluation. . Bone Marrow Transplantation, Vol:33,
Suppl 1, abstract P904, S250, 2004.
79. Bregni M, Peccatori J, Barkholt L, Ringden O, Pedrazzoli P, Martino R, Lenhoff
S, Corradini P, Demirer T, Niederwieser D. Prognostic factors for survival in renal cell
cancer patients undergoing allogeneic stem cell transplantation: A report from the EBMt
Solid Tumors Working Party. ASCO Proceedings, Vol: 22, No: 14S,, Abstr 6666, page
599s, 2004.
80. Giorgi U. De, Demirer T, Wandt H, et al. Second line high-dose chemotherapy
in patients with extragonadal nonseminomatous germ cell tumors: the experience of the
European Group for Blood and Marrow Transplantation (EBMT). Annals of Oncology,
Vol: 15, Suppl:3, iii 121, abstract (Poster) 452P, 2004.
65
65
81. Bay JO, Durando X, Linassier C, Biron P, Kwiatkowski F, Verelle P, Rosti G,
Demirer T, on behalf of the Solid Tumors Working party. High dose BCNU followed by
autologous hematopoietic stem cell transplantation in supratentorial high-grade
malignant gliomas: An EBMT retrospective analysis of 218 patients. Bone Marrow
Transplantation, Vol: 35, Suppl 2, Abstract (Oral Presentation) 0272, S53, 2005,
82. Grosso F, Corradini P, Carrabba M, Castagna L, Pedrazzoli P, Gobel U, Demirer
T, Niederwieser D, on behalf of Solid Tumors Working party. Allogeneic stem cell
transplantation in advanced soft tissue sarcomas: a retrospective analysis on the EBMT
STWP. Bone Marrow Transplantation, Vol: 35, Suppl 2, Abstract (Oral Presentation)
0272, S53, 2005,
84. İlhan O, Topcuoglu P, Arat M, Soydan E, Özcan M, Gürman G, Demirer T, Akan
H et al. Allogeneic hematopoietic stem cell transplantation in acute myeloblastic
leukemia.: İbn-i Sina experience (1989-2004). Bone Marrow Transplantation, Vol: 35,
Suppl 2, Abst (Oral Presentation) 0272, S53, 2005,
85. Pervin Topçuoğlu, Taner Demirer et all. When to start G-CSF after mobilization
regimen? Any impact on stem cell collection efficiency (abstract 141, sayfa: 231). The
15th Congress of the ESFH (Transfusion and Apheresis Science, 2005; 33(2)
86. M Özcan, M K Yüksel, P Topçuoğlu, E A Soydan, S K Toprak, M Beksaç, A Uysal,
H Akan, T Demirer, et all. Addition of ANTI-CD20 to high dose chemotherapy with
autologous peripheral blood stem cell transplantation prolong disease free survivalin
non-Hodgkin’s lymphomas: A Matched-controlled analysis (Abstract: 573 Poster: 480).
XXX. World Congress of the International Society of Hematology. Turkish Journal of
Haematology, 2005 22(3) (supplement)
66
66
87. P Topçuoğlu, F EKiz, E A Soydan, M K Yüksel, S K Toprak, M Özcan, Ö Arslan, G
Gürman, T Demirer, et all. How to calculate the quantity of CD34(+) cells infused? A
single center cohort study based on actual, ideal or adjusted ideal body body weight
(Abstract: 668 Poster: 575). XXX. World Congress of the International Society of
Hematology. Turkish Journal of Haematology, 2005 22(3) (supplement)
88. O İlhan, P Topçuoğlu, M Arat, E A Soydan, M K Yüksel, S K Toprak, Ö Arslan, M
Özcan, G Gürman, T Demirer et all. Allogeneic hematopoietic cell transplantation in
acute myeloblastic leukemia: Ankara University Experience (Abstract: 672 Poster: 579).
XXX. World Congress of the International Society of Hematology. Turkish Journal of
Haematology, 2005 22(3) (supplement)
89. P Topçuoğlu, Ö T İyidir, K Dalva, E A Soydan, M K Yüksel, S K Toprak, H Koç, A
Uysal, M. Beksaç, M Özcan, M Arat, T Demirer et all. When to start G-CSF after
mobilization regimen? Any impact on stem cell collection efficiency (Abstract: 759
Poster: 666). XXX. World Congress of the International Society of Hematology. Turkish
Journal of Haematology, 2005 22(3) (supplement)
90. Gökhan Kabaçam, Mutlu Arat, Ender Soydan, Klara Dalva, Erol Ayyıldız, Günhan
Gürman, Taner Demirer, Hamdi Akan, Meral Beksaç, Osman İlhan. Factors effecting
peripheral stem cell collection in multiple myeloma patients.(poster 612), S:127.
Haematologica 2005, suppl 10th International Myeloma Workshop, Sydney, April 10-14,
2005
91. O. Ilhan, P. Topcuoglu, M. Arat, E. Soydan, S.K. Toprak, M.K. Yuksel, C. Ustün, H.
Celebi, I. Dilek, O. Arslan, M. Ozcan, G. Gurman, T. Demirer, H. Akan, M. Beksac, A.
Uysal, N. Konuk, H. Koc. Allogeneic haematopoietic cell transplantation in acute
67
67
myeloblastic laeukemia: Ibni Sina experience (1989 - 2004) 31st Annual Meeting of the
European Group for Blood and Marrow Transplantation 20-23 March 2005
92. P. Topçuoğlu, ÖT. İyidir, K. Dalva, EA. Soydan, MK. Yüksel, SK. Toprak, H Koç,
VA Uysal, M. Beksaç, M. Özcan, Ö. Arslan, N. Konuk, M. Arat, T. Demirer, O. İlhan.
When to start G-CSF after mobilization regimen? Any impact on stem cell collection
efficiency. Turk J Haematol 2005; 22: 312 (P 666)
93. Aglietta M, Barkholt L, Niederwieser D, Ringden O, Demirer T. Allogeneic
hematopoietic cell transplantation after reduced intense conditioning as adoptive cell
therapy in resistant metastatic colorectal carcinoma. The European Experience.
Journal of Clinical Oncology, Vol: 24, No: 18s, Part I, 2006.
94. Arat M, Cengiz G, Ayyıldız E, Topçuoğlu P, Arslan Ö, Özcan M, Gürman G,
Dalva K, Beksaç M, Demirer T, et all . Retrospective validation of an apheresis cycle
calculator of autologous PBSC collection in myeloma and malignant lymphoma
patients. Abstract Book, ESFH 2006 Meeting, 20-21 June 2006, Umea, Sweden (Oral
Presentation).
95. Arat M, Soydan E, Cengiz G, Ayyildiz E, Topcuoglu P, Arslan O, Ozcan M,
Gurman G, Dalva K, Beksac M, Demirer T, et all. Retrospective validation of an
apheresis cycle calculator on autologous PBSC collection in myeloma and malignant
lymphoma patients. CYTOTHERAPY 8: Suppl. 1, 2006.
96. Aglietta M, Barkholt L, Caravelli D, Omazig B, Ciccone G, Niederwieser D, Ringden
O, Demirer T on behalf of EBMT STWP. Allogeneic hematopoietic cell transplantation
after reduced intense conditioning as adoptive cell therapy in resistant metastatic
colorectal carcinoma. The European Experience. 24, No 18S Part I of II, Poster 3596, J
Clin Oncol, 2007.
68
68
97. Arat M, Gurman G, Demirer T, Beksaç M et al. Time intervals preceeding
autologous stem cell transplantation in multiple myeloma patients : a single center
intent to transplant analysis. Bone Marrow Transplantation, Vol: 39, Suppl 1, Abstract
R1172, S322, 2007.
98. Serbest E, Ozcan M, Arslan O, Demirer T, Beksac M, Arat M et al. The impact of
disparity in short tandem repeats analysis on the outcome of allogeneic haematopoietic
cell transplantation from HLA identical sibling donors. Bone Marrow Transplantation,
Vol: 39, Suppl 1, Abstract P799 , S197-198, 2007.
99. Soydan E, Arslan O, Ozcan M, Demirer T, Arat M et al. The impact of
histopathological subtype of cutaneous chronic GVHD on alloHSCT outcome: lichenoid
versus sclerodermoid. Bone Marrow Transplantation, Vol: 39, Suppl 1, Abstract P549,
S106-107, 2007.
100. Ugur Bİlgin A, Soydan E, Akan H, Gurman G, Demirer T, Arat M et al. The
impact of pretransplant imatinib use in allogeneic HSCT for CML: a single center
comparative analysis. Bone Marrow Transplantation, Vol: 39, Suppl 1, Abstract P444,
S68-69, 2007,
101. P. Topcuoglu, S. Civriz Bozdağ, B. Ceydilek, MK Yüksel, ŞM Bakanay, Ö.
Arslan, T Demirer, et all. EMA as a salvage regimen in patiens with refractory/relapse
AML: A single center experience. Turk J Hematol 2007; 1 (suppl 1): 110-111
102. E. Serbest, P. Topcuoglu, K. Dalva, E.A. Soydan, O. Arslan, M. Ozcan, T.
Demirer, et all. The impact of disparity in short tandem repeats analysis on the
69
69
outcome of allogeneic haematopoietic cell transplantation from HLA-identical sibling
donors. Haematologica, the Hematology Journal 2007; 92 (suppl 1): 517
103. Bay J.O, Tabrizi R, Blaise D, Viens P, Ehninger G, Slavin S, Rosti G, Demirer T ,
Bregni M. Allogeneic stem cell transplantation in ovarian cancer. The EBMT
experience. Bone Marrow Transplantation, S 310, p 998, 2008.
104. Bertuzz. A, Tienghi A, Pedrazzoli P, Castagna L, Demirer T, Bregni M. Long
term outcome in adult Ewing’s sarcoma patients treated with high-dose chemotherapy :
results of a retrospective analysis of the EBMT. Bone Marrow Transplantation, S 311, p
999, 2008.
105. Demirer T, Ueno N, Bregni M, Berry D, on behalf of the MDACC-EBMT Meta-
analysis Group. High-dose chemotherapy with a stem cell support-versus-standard
dose chemotherapy: meta-analysis of individual patient data from 15 randomised breast
cancer trial. (Oral Presentation). Bone Marrow Transplantation, S 311, p 999, 2008.
106. DA Berry, NT Ueno, MM Johnson, X Lei, D Smith, J Caputo, L Yancey, M
Bregni, T Demirer, on behalf of MDACC-EBMT Meta-analysis Group. High-dose
chemotherapy with autologous stem-cell support versus standard-dose chemotherapy:
meta-analysis of individual patient data from 6 randomized metastatic breast cancer
trials. 31st Annual San Antonio Breast Cancer Symposium. Abstr No: 551494, 2008.
107. Demirer T, Ueno N, Johnson M, Bregni M, Berry DA, on behalf of the EBMT-
MDACC Meta-analysis group. High-dose chemotherapy with autologous stem-cell
support versus standard-dose chemotherapy: meta-analysis of individual patient data
from 6 randomised metastatic breast cancer trials. Oral Presentation. Bone Marrow
70
70
Transplantation, Vol: 43, Suppl 1, O156, S16, 2009.
108. Civriz BS, Topcuoglu P, Bakanay s, Arat M, Beksac M, Arslan Ö, Demirer T,
Gurman G, Ozcan M. The effect of rituximab in first line therapy results of autologous
hematopoietic stem cell transplantation in relapsed non-Hodgkin’s lymphoma patients.
Bone Marrow Transplantation, Vol: 43, Suppl 1, O156, S16, 2009.
109. Demirer T, Ueno N, Johnson M, Bregni M, Berry DA, on behalf of the EBMT-
MDACC Meta-analysis group. High-dose chemotherapy with autologous stem-cell
support versus standard-dose chemotherapy: meta-analysis of individual patient data
from 6 randomised metastatic breast cancer trials. Oral Presentation. Bone Marrow
Transplantation, Vol: 43, Suppl 1, O156, S16, 2009.
110. Civriz BS, Topcuoglu P, Bakanay S, Arat M, Beksac M, Arslan Ö, Demirer T,
Gurman G, Ozcan M. The effect of rituximab in first line therapy results of autologous
hematopoietic stem cell transplantation in relapsed non-Hodgkin’s lymphoma patients.
Bone Marrow Transplantation, Vol: 43, Suppl 1, O156, S16, 2009.
111. S.C Bozdağ, P Topcuoglu, M. Arat, T. Demirer, M. Beksac, N. Konuk, A. Uysal,
G. Gürman. Comparison of two different chemotherapy regimens for peripheral blood
stem cell mobilization in Lymphoma. Bone Marrow Transplantation. Vol 45, Suppl 2,
P841, 2010.
2013-2014 (Yayın Yılı)
112.Comparison Of Flow Cytometric and Clinical Findings In Patients
71
71
With Paroxysmal Nocturnal Hemoglobinuria
By: Demirer, Taner; Baslar, Suphi; Uysal, Vasif Akin; et al.
Conference: 55th Annual Meeting of the American-Society-of-Hematology
Location: New Orleans, LA Date: DEC 07-10, 2013
Sponsor(s): Amer Soc Hematol
BLOOD Volume: 122 Issue: 21 Meeting Abstract: 4877 Published: NOV 15
2013
113. Aldehyde hydrogenase activity in mobilized peripheral stem cell
products and its relationship with engraftment
By: Bozdag, S. Civriz; Topcuoglu, P.; Ozkan, M.; et al.
Conference: 39th Annual Meeting of the European-Group-for-Blood-and-Marrow-
Transplantation (EBMT) Location: London, ENGLAND Date: APR 07-10, 2013,
European Grp Blood & Marrow Transplantat (EBMT)
BONE MARROW TRANSPLANTATION Volume: 48 Supplement: 2 Pages:
S196-S196 Published: APR 2013
114. Atilla E, Ataca P, Bozdag SC, Toprak SK, Yuksel MK, Topcuoglu P, Arslan O,
Ozcan M, Demirer T, Ilhan O, Akan H, Beksac M, Gurman G,’Is initial CD3+ T cell dose
in donor lymphocyte infusion for relapsed hematological malignancies a prognostic
determinant?’, ASH Meeting, Chicago, USA, BLOOD, 2013.
72
72
115. Management of Hemorrhagic Cystitis after Allogeneic
Hematopoietic Stem Cell Transplantation
By: Gurman, Gunhan; Atilla, Erden; Ozen, Mehmet; et al.
Conference: BMT Tandem Meetings Location: Grapevine, TX Date: FEB 26-MAR
02, 2014 BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION Volume:
20 Issue: 2 Supplement: 1 Pages: S194-S195 Meeting Abstract: 290
Published: FEB 2014
116. Gunduz M, Ataca P, Ozen M, Atilla E, Bozdag SC, Toprak SK, Topcuoglu P,
Ozcan M,DemirerT, Beksac M, Akan H, Gurman G, Arslan O, ‘Do FMS-like Tyrosine
Kinase 3 and Nucleophospmin 1 Gene Mutation Really Effect Survival in Acute Myeloid
Leukemia?’,Orlando, FL, USA. Poster presentation,57th ASH Meeting, BLOOD, 2014.
117. Atilla E, Sahin U, Ataca P, Bozdag SC, Toprak SK, , Arslan O, Demirer T, Akan
H, Gurman G, Beksac M, Ilhan O, Konuk N, Ozcan M, ‘Is R-CODOX-M/IVAC Inferior to
Other Regimens in Burkitt’s Lymhoma: A Single Center Experience’, Orlando, FL, USA.
57th ASH Meeting Poster presentation, BLOOD, 2014.
2015 (Yayın Yılı)
118. Ataca P, Atilla E, Arslan O, Ozcan M, Demirer T, Akan H, Beksac M, Konuk N,
Gurman G, Ilhan O, ‘Are there any optimal cell doses for graft repopulation in the Bone
Marrow-Derived Allogeneic Hematopoietic Stem Cell Transplantations?’, Istanbul,
Turkey, 41th EBMT Meeting, Poster presentation, Bone Marrow Transplantation,
2015.
73
73
119. Atilla E, Ataca P, Ozcan M, Demirer T, Ilhan O, Akan H, Beksac M, Konuk N,
Gurman G, ‘Upper and Lower Respiratory Tract Infections by Respiratory Viruses by
Respiratory Viruses in Adult Recipients of Allogeneic Hematopoietic Stem Cell
Transplantation: Single Center Experience’. 41st EBMT Meeting, Istanbul, Turkey,
Poster Presentation, Bone Marrow Transplantation, 2015.
120. Topcuoglu P, Yuksel MK, Arslan O, Ozcan M, Demirer T, Ilhan O, Akan H,
Konuk N, Gurman G,’ The Relapse in acute leukemia after allogeneic hematopoietic
stem cell transplantation: No approaches have been superior yet’. . 41st EBMT Meeting,
Istanbul, Turkey, Poster Presentation, Bone Marrow Transplantation, 2015.
121. Atilla E, Gunduz M, Ataca P, Bozdag SC, Toprak SK, Yuksel MK, Topcuoglu P,
Arslan O, Ozcan M, Demirer T, Ilhan O, Akan H, Beksac M, Konuk N, Gurman
G,’Autologous Stem Cell Transplantation in Elderly Patients with Myeloma or
Lymphoma’, Best of ASBMT Tandem Meetings, Poster Presentation May 2015
Ankara, Turkey, Best Abstract Award.
122. Atilla E, Ataca P, Bozdag SC, Toprak SK, Yuksel MK, Topcuoglu P, Arslan O,
Ozcan M, Demirer T, Ilhan O, Akan H, Beksac M, Gurman G,’Is initial CD3+ T cell
dose in donor lymphocyte infusion for relapsed hematological malignancies a
prognostic determinant?’, ASH Meeting on Hematologic Malignancies, Poster
Presentation September 2015 Chicago USA
123. Atilla E, Gunduz M, Ataca P, Bozdag SC, Toprak SK, Yuksel MK, Topcuoglu P,
Arslan O, Ozcan M, Demirer T, Ilhan O, Akan H, Beksac M, Konuk N, Gurman
G,’Autologous Stem Cell Transplantation in Elderly Patients with Myeloma or
Lymphoma’, 20th EHA Meeting, Poster Presentation June 2015 Vienna, Austria
74
74
124. Ataca P, Atilla E, Aydin T, Merter M, Bozdag SC, Toprak SK, Yuksel MK,
Topcuoglu P, Arslan O, Ozcan M, Demirer T, Ilhan O, Beksac M, Akan H, Konuk N,
Gurman G, ‘Allogeneic Stem-Cell Transplantation for Hodgkin and non-Hodgkin
Lymphoma’ 5th ICLLM Meeting, Poster Presentation May 2015 Istanbul, Turkey..
125. Gunduz M, Atilla E, Ataca P, Pekcan G, Bozdag SC, Toprak SK, Yüksel MK,
Topcuoglu P, Arslan O, Ozcan M, Demirer T, Ilhan O, Akan H, Beksac M, Konuk N,
Gurman G. Autologous Stem Cell Transplantation in Elderly Patients ( >=60 years) with
Myeloma or Lymphoma: Single Center Experience 41th EBMT Meeting, Poster
Presentation March 2015 Istanbul, Turkey
126. Ataca P, Atilla E, Altas U, Bay M, Dalva K, Bozdag SC, Toprak SK, Yüksel MK,
Topcuoglu P, Arslan O, Ozcan M, Demirer T, Akan H, Beksac M, Konuk N, Gurman G,
Ilhan O. Are there any optimal cell doses for graft repopulation in the Bone Marrow-
Derived Allogeneic Hematopoietic Stem Cell Transplantations?41th EBMT Meeting,
Poster Presentation March 2015 Istanbul, Turkey.
127. Pekcan G, Ateşoglu B, Merter M, Topcuoglu P, Bozdag SC, Toprak SK, Yüksel
MK, Ates O, Özcan M, Demirer T. Different Doses of Anti-Thymocyte Globulin (ATG) in
the Conditioning Regimen for Allogeneic Hematopoetic Stem Cell Transplantation 41th
EBMT Meeting, Poster Presentation March 2015 Istanbul, Turkey.
128. Yuksel MK, Pekcan G, Edipoğlu E, Bay M, Civriz S, Toprak SK, Topcuoglu P,
Arslan O, Ozcan M, Beksac M, Demirer T, Akan H, Konuk N, Gurman G, Ilhan O. Is it
possible to overcome the catastrophic complications of Hematopoietic Stem Cell
Transplantation (HSCT) using Plasma Exchange (PE)?: A Single Center's Experience
41th EBMT Meeting, Poster Presentation March 2015 Istanbul, Turkey.
75
75
129. Bozdag SC, Kırcalı E, Ataca P, Atilla E, Bay M, Toprak SK, Yüksel MK, Topcuoglu
P, Arslan O, Özcan M, Demirer T, İlhan O, Akan H, Beksac M, Konuk N, Gurman G. Is
there an optimum CD3+T cell dose for donor lymphocyte infusion? 41th EBMT Meeting,
Poster Presentation March 2015 Istanbul, Turkey.
130. Sahin U, Erdal H, Bozdag SC, Toprak SK, Yuksel MK, Topcuoglu P, Arslan O,
Ozcan M, Demirer T, Ilhan O. Impact of Pre-transplant Serum Ferritin on Outcomes of
Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia. 41th EBMT
Meeting, Poster Presentation March 2015 Istanbul, Turkey
131. Topcuoglu P, Gultay D, Ozturk N, Kılıc O, Okay M, Karadag YE, Cınar H, Ataca P,
Atilla E, Bozdag SC, Toprak SK, Yüksel MK, Arslan O, Özcan M, Demirer T, Akan H,
Beksac M, Konuk N, Gurman G. Generic (Bioequivalent) Melphalan Has Similar
Efficacy and Toxicity but Lower Cost in the Conditioning Regimen for Autologous
Hematopoietic Stem Cell Transplantation 41th EBMT Meeting, Poster Presentation
March 2015 Istanbul, Turkey.
132. Gurman G, Ataca P, Aydın T, Atilla E, Bozdag SC, Toprak SK, Yüksel MK,
Topcuoglu P, Ozcan M, Demirer T. Allogeneic stem cell transplantation results in our
myelodysplastic syndrome (MDS) patients. Annual Meeting of the American-Society-
of-Clinical-Oncology (ASCO), Haziran 2015 Chicago, USA.
133. Gurman G, Ataca P, Atilla E, Bozdag SC, Toprak SK, Yuksel MK, Demirer T, Akan H,
Arslan O, Topcuoglu P, Beksac M, Ilhan O, Ozcan M. Positive Impact of Chronic Graft-Versus
Host Disease on Survival in 928 Allogeneic Hematopoietic Stem Cell Transplant Recipients.
December 3, 2015; Blood: 126 (23)
76
76
134. Mustafa Merter, Erden Atilla, Ugur Sahin, Sinem Civriz Bozdag, Meltem Kurt
Yuksel, Pervin Topcuoglu, Onder Arslan, Muhit Ozcan, Taner Demirer, Gunhan
Gurman, Osman Ilhan, Hamdi Akan, Meral Beksac, Selami Kocak Toprak. Comparison
of Two Different Doses of Corticosteroid Premedication for Antithymocyte Globulin in
Allogeneic Hematopoietic Stem Cell Transplantation Blood 2015 126:5456; published
ahead of print December 4, 2015
135. Erden Atilla, Pinar Ataca, Selami Kocak Toprak, Meltem Kurt Yuksel, Pervin
Topcuoglu, Onder Arslan, Muhit Ozcan, Taner Demirer, Osman Ilhan, Meral Beksac,
Hamdi Akan, Gunhan Gurman, Sinem Civriz Bozdag.Is Initial CD3+ T Cell Dose in
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies a Prognostic
Determinant? Blood 2015 126:5483; published ahead of print December 4, 2015
2016 (Yayın Yılı)
136. THERAPEUTIC PLASMA EXCHANGE FOR THROMBOTIC
MICROANGIOPATHY.By: E. Atilla, P. Ataca, U. Sahin, S.C. Bozdag, S.K. Toprak, M.K.
Yuksel,P. Topcuoglu, O. Arslan, T. Demirer, M. Ozcan, H. Akan, M. Beksac,G. Gurman,
O. Ilhan.Conference: 24th Biennial International Congress on Thrombosis / EMLTD
Congress Location: Istanbul, TURKEY Date: MAY 04-07, 2016
137. THERAPEUTIC THROMBOCYTAPHERESIS: HIGHER PLATELET COUNTS
SHOULD MATTER. By: Narli, Z.; Sahin, U.; Bozdag, S. C.; M.K. Yuksel, S.K. Toprak,
P. Topcuoglu,M. Ozcan, O. Arslan, T. Demirer, M. Beksac, G. Gurman, O. Ilhan: 24th
77
77
Biennial International Congress on Thrombosis / EMLTD Congress Location: Istanbul,
TURKEY Date: MAY 04-07, 2016 Sponsor(s): EMLTD. THROMBOSIS
RESEARCH Volume: 141 Supplement: 1 Pages:S81-S82 Meeting
Abstract: C0323 Published: MAY 2016 (Poster)
138. Effect of Cytomegalovirus Reactivation on Prognosis After Allogeneic
Transplantation for Acute Leukemia with Active Disease Conditioned with a Sequential
Regimen and Anti-Thymocyte Globulin. By: M. Gunduz, M. Kurt Yuksel,*, U. Sahin, M.
Merter, Z. Narli,Ozdemir, S. Civriz Bozdag, S. K. Toprak, P. Topcuoglu,O. Arslan, M.
Ozcan, T. Demirer, O. Ilhan, H. Akan,M. Beksac, G. Gurman. Conference: 42nd
Annual Meeting of the European-Society-for-Blood-and-Marrow-
Transplantation Location: Valencia, SPAIN Date: APR 03-06, 2016
139. Efficacy of High Dose Corticosteroid Premedication for the Prevention of Anti-
thymocyte Globulin Related Side Effects. By: M. Merter, U. Sahin, E. Atilla, S. Civriz
Bozdag, M. Kurt Yüksel,P. Topcuoglu, O. Arslan, M. Ozcan, T. Demirer, O. Ilhan, H.
Akan, M. Beksac, G. Gurman, S. K. Toprak,*Conference: 42nd Annual Meeting of the
European-Society-for-Blood-and-Marrow-Transplantation Location: Valencia,
SPAIN Date: APR 03-06, 2016
140. Therapeutic Plasma Exchange for Thrombotic Microangiopathy
Osman Ilhan, Erden Atilla, Pinar Ataca Atilla, Sinem Civriz Bozdag, Selami
Toprak, Pervin Topcuoglu,Hamdi Akan, Taner Demirer, Meral Beksac, Onder Arslan,
Muhit Ozcan and Gunhan Gurman. ASH Annual Meeting 2016 3-6 December 2016.
Blood 2016 128:4939
141. Comparison of Reduced Intensity Conditioning (RIC) Regimen and Myeloablative
Conditioning (MAC) Regimen in Allogeneic Hematopoietic Stem Cell Transplantation (Allo-
78
78
HSCT) for Adult Patients with Acute Leukemia. Gunhan Gurman, Gozde Aydemir
, Erden Atilla, Pinar Atilla, Onder Arslan, Muhit Ozcan, Taner Demirer, Osman Ilhan, H
amdi Akan and Meral Beksac. ASH Annual Meeting 2016 3-6 December 2016.
Blood 2016 128:5757
142. Ilhan O, Atilla E, Ataca P, Bozdag SC, Toprak SK, Yüksel MK, Topcuoglu P,
Arslan O, Ozcan M, Demirer T, Akan H, Beksac M, Gurman G. Age as a dicision factor
for doing autuologous stem cell transplantation in fit patients with myeloma and
lymphoma. ASCO Annual Meeting. J Clin Oncol 34, 2016 (suppl; abstr e 19001)